

(19) AUSTRALIAN PATENT OFFICE

(54) Title
MHC class I peptide epitopes from the human 5T4 tumor-associated antigen

(51)⁶ International Patent Classification(s)
C07K 14/47 (2006.01) 20060101ALI2005100
C07K 1/06 (2006.01) 8BMEP **C12N**
C12N 15/12 (2006.01) 15/12
A61K 39/00 (2006.01) 20060101ALI2006052
C07K 14/47 1BWO **A61K**
20060101AFI2005100 39/00
8BMEP **C07K** 20060101ALN200510
1/06 08BMEP
PCT/GB03/00670

(21) Application No: 2003207321

(22) Application Date: 2003 .02 .13

(87) WIPO No: W003/068816

(30) Priority Data

(31) Number	(32) Date	(33) Country
0203419.7	2002 .02 .13	GB

(43) Publication Date : 2003 .09 .04

(43) Publication Journal Date : 2003 .10 .02

(71) Applicant(s)
Oxford BioMedica (UK) Limited, IDM, S. A.

(72) Inventor(s)
carroll, miles, Kingsman, Susan, Redchenko, Irina

(74) Agent/Attorney
Wrays, Ground Floor 56 Ord Street, West Perth, WA, 6005

(56) Related Art
AU2002214150
WO 00/29428

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 August 2003 (21.08.2003)

PCT

(10) International Publication Number
WO 03/068816 A1

(51) International Patent Classification⁷: C07K 14/47,
7/06, C12N 5/10, 15/12, C07K 16/18, C12Q 1/68, G01N
33/53

(21) International Application Number: PCT/GB03/00670

(22) International Filing Date: 13 February 2003 (13.02.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0203419.7 13 February 2002 (13.02.2002) GB

(71) Applicant (for all designated States except US): OXFORD
BIOMEDICA UK LIMITED [GB/GB]; Medawar Cen-
tre, Robert Robinson Avenue, The Oxford Science Park,
Oxford OX4 4GA (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CARROLL, Miles
[GB/GB]; Oxford BioMedica UK Limited, Medawar
Centre, Robert Robinson Avenue, The Oxford Science

Park, Oxford OX4 4GA (GB). KINGSMAN, Susan
[GB/GB]; Oxford BioMedica UK Limited, Medawar Cen-
tre, Robert Robinson Avenue, The Oxford Science Park,
Oxford OX4 4GA (GB). REDCHENKO, Irina [GB/GB];
Oxford BioMedica UK Limited, Medawar Centre, Robert
Robinson Avenue, The Oxford Science Park, Oxford OX4
4GA (GB).

(74) Agents: MASCHIO, Antonio et al.; D Young & Co, 21
New Fetter Lane, London EC4A 1DA (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI,

[Continued on next page]

(54) Title: MHC CLASS I PEPTIDE EPITOPES FROM THE HUMAN 5T4 TUMOR-ASSOCIATED ANTIGEN

	Target cells	Auto LCI	Auto LCI+	Auto LCI+	Auto LCI+	Auto LCI+	Auto LCI+	Auto LCI+	Auto LCI+	Auto LCI+	Auto LCI+
		p77	c1	c2	c3	c4	c5	c6	c7	c8	
Spont /Max	81 / 1238	95 / 1127	78 / 1089	86 / 1152	97 / 1182	94 / 1184	68 / 1077	80 / 1063	79 / 1145	86 / 942	
Clone No.											
14	73	69	76	70	74	73	78	72	73	76	
15	13	9	10	6	12	8	27	12	10	10	
21	9	8	9	7	10	6	8	11	8	10	
32	22	21	21	22	22	21	23	22	22	23	
95	44	41	44	37	43	39	45	44	46	50	
40	32	30	32	25	28	28	32	33	32	34	

c1 NGADLSPPAF
c2 WFADLSPPAF
c3 PADLSPPAF
c4=2/1 PADLSPPAF
c5 PADLSPPAF
c6 PADLSPPAF
c7 PADLSPPAF
c8 ADLSPPAF



(57) Abstract: There is provided an MHC class I peptide epitope from 5T4 antigen. In particular, there is provided a peptide epitope of 5T4 which comprises one of the following: (i) the amino acid sequence shown as SEQ ID No.2; (ii) the minimal epitope from the amino acid sequence shown as SEQ ID No.3; (iii) the minimal epitope from the amino acid sequence shown as SEQ ID No.4. (iv) the minimal epitope from the amino acid sequence shown as SEQ ID No. 5. (v) the minimal epitope from the amino acid sequence shown as SEQ ID No.6. (vi) the minimal epitope from the amino acid sequence shown as SEQ ID No.7. There is also provided a vaccine comprising such a peptide (or precursor thereof) and its use to treat and/or prevent a disease, in particular a cancerous disease.



SK, TR), OAPI patent (BE, BJ, CE, CG, CI, CM, GA, GN, CQ, GW, MI., MR, NE, SN, TD, TG).

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

— with international search report

MHC CLASS I PEPTIDE EPITOPES FROM THE HUMAN 5T4 TUMOR-ASSOCIATED ANTIGEN

Field of the Invention

- 5 The present invention relates to peptide epitopes of 5T4 antigen, and their use in immunotherapy.

Background to the Invention

- 10 Prior to the identification of specific human tumour antigens, many clinical trials were performed attempting to immunise cancer patients against either whole cancer cells or subcellular fractions from cancer cells. The identification of genes encoding tumour antigens, however, has made it possible to develop specific immunotherapies based on attacking tumour cells bearing the identified antigens. A variety of clinical approaches utilising these
- 15 genes or gene products are possible as summarised in the following table.

Active immunotherapy ("Cancer vaccines") 1. Immunisation with: i) purified antigen ii) immunodominant peptide (native or modified) iii) "naked" DNA encoding the antigen iv) recombinant viruses encoding the antigen v) antigen presenting cells pulsed with protein or peptide (or transfected with genes encoding the antigen) 2. Use of cytokine adjuvants such as IL-2 and IL-12 administered systemically or encoded by the immunising vector	Passive immunotherapy ("Adoptive immunotherapy") 1. Transfer of cells sensitized in vitro to the specific antigen (bulk or cloned populations) 2. Transduction of effector cells (or stem cells) with genes encoding T cell receptors that recognise sepcific antigens.
---	--

- Immunisation with intact protein has the potential advantage of simultaneously immunising against both class I and class II epitopes but requires extensive and time-consuming efforts to
- 20 purify large amounts of tumour antigen. The identification of class I and class II peptide

within a tumour antigen makes it possible to immunise with high levels of pure synthetic peptide. The peptide approach also has the advantage that one can choose between a class I and a class II type response (or mixture) by choosing which epitopes to use. Immunisation with peptide also means that subdominant and/or cryptic epitopes can be chosen (as the need
 5 for antigen processing may be bypassed or reduced to a "trimming role) in order to stimulate a different subset of T cells. Also the peptide may be modified (for example at their HLA class I or II anchor sites) to increase their immunogenicity.

In the past few years, much attention has been given to the role of CD8+ T cells in tumour
 10 immunity. Tumour-specific CD8+ CTLs have been shown to be capable of lysing tumour cells directly and eradicating tumour masses *in vivo* in animal models. However, CD4+ T cells are also thought to play a critical role (Wang and Rosenberg (1999) Immunological Reviews 170:85-100) and it may be that optimal cancer vaccines require the participation of both CD4+ and CD8+ T cells.

A number of oncofoetal or tumour-associated antigens (TAAs) have been identified and characterised in human and animal tumours. In general, TAAs are antigens expressed during foetal development which are downregulated in adult cells, and are thus normally absent or present only at very low levels in adults. Tumour cells have been observed to resume
 20 expression of TAAs, and the application of TAAs for tumour diagnosis, targeting and immunotherapy has therefore been suggested.

The TAA 5T4 (see WO 89/07947) has been previously characterised. It is a 72kDa glycoprotein expressed widely in carcinomas, but having a highly restricted expression
 25 pattern in normal adult tissues (see Table 1). It appears to be strongly correlated to metastasis in colorectal and gastric cancer. The full nucleic acid sequence of human 5T4 is known (Myers *et al.*, 1994 J Biol Chem 169: 9319-24).

Table 1

Distribution of Human 5T4

Tumour	5T4	Frequency
Type	(%)	
Breast	84	

Ovarian 71
 Gastric 74
 Colorectal 85

- (Starzynska *et al.*, Eur J Gastroenterol Hepatol 1998 Jun; 10 (6): 479-84; Starzynska *et al.*,
 5 Br J Cancer 1994 May; 69 (5): 899-902; Starzynska *et al.*, Br J Cancer 1992 Nov; 66 (5):
 867-9)

5T4 has been proposed as a marker, with possible mechanistic involvement, for tumour
 progression and metastasis potential (Carsberg *et al.*, (1996) Int J Cancer 1996 Sep 27; 68
 (1) : 84-92). 5T4 has also been proposed for use as an immunotherapeutic agent (see WO
 10 00/29428).

Summary of the Invention

The present inventors have identified a number of MHC class I and II restricted epitopes
 of 5T4. The identification of particular antigenic peptides provides new opportunities for
 the development of diagnostic and therapeutic strategies against cancer.

- 15 Thus the first aspect of the present invention relates to MHC class I epitopes of 5T4
 antigen.

The invention provides peptide epitopes of 5T4 antigen which are capable of being
 presented in conjunction with an MHC class I molecule such that they are specifically
 recognised by a T cell.

- 20 In particular, the present invention provides a peptide epitope of 5T4 which comprises one
 of the following: (i) the amino acid sequence shown as SEQ ID No. 2; (ii) the minimal
 epitope from the amino acid sequence shown as SEQ ID No. 3; (iii) the minimal epitope
 from the amino acid sequence shown as SEQ ID No. 4.

(iv) the minimal epitope from the amino acid sequence shown as SEQ ID No. 5.

- 25 (v) the minimal epitope from the amino acid sequence shown as SEQ ID No. 6.

(vi) the minimal epitope from the amino acid sequence shown as SEQ ID No. 7.

The present invention also provides an isolated MHC Class I peptide epitope of 5T4 which
 comprises one of the following:

- (i) the amino acid sequence shown as SEQ ID No. 2;

- 3/2 -

- (ii) the minimal epitope from the amino acid sequence shown as SEQ ID No. 3;
- (iii) the minimal epitope from the amino acid sequence shown as SEQ ID No. 4.
- (iv) the minimal epitope from the amino acid sequence shown as SEQ ID No. 5.
- (v) the minimal epitope from the amino acid sequence shown as SEQ ID No. 6.
- 5 (vi) the minimal epitope from the amino acid sequence shown as SEQ ID No. 7.

Further aspects of the invention relate to: -

a polypeptide string comprising such a peptide.

- such a peptide epitope, or such a polypeptide string in association with a cell penetrator.
- such a peptide epitope, or such a polypeptide string associated with a tetramer.
- a nucleic acid sequence capable of encoding such a peptide epitope or polypeptide string (and optionally an associated cell penetrator).
- 5 - a vector system capable of delivering such a nucleic acid sequence to a cell.
- a cell pulsed with such a peptide epitope (or a precursor thereof).
- a vaccine comprising such a peptide epitope, a polypeptide string, nucleic acid sequence, vector system and/or cell.
- the use of such a vaccine in the manufacture of a medicament for use in the prevention and/or treatment of a disease.
- 10 - a method for treating and/or preventing a disease in a subject in need of same which comprises the step of administering an effective amount of such a vaccine to the subject.
- an agent capable of binding specifically to such a peptide and/or nucleic acid sequence.
- a method which comprises the step of detecting the presence of such a peptide, nucleic acid or agent in a subject.
- 15 - a T cell line or clone capable of specifically recognising such a peptide epitope in conjunction with an MHC class I molecule.

Other aspects of the present invention are presented in the accompanying claims and in the following description and discussion. These aspects are presented under separate section headings. However, it is to be understood that the teachings under each section heading are not necessarily limited to that particular section heading.

20

Detailed description of the invention

25

Epitopes

The present invention relates to peptide epitopes.

- 30 The term "peptide" is used in the normal sense to mean a series of residues, typically L-amino acids, connected one to the other typically by peptide bonds between the α -amino and carboxyl groups of adjacent amino acids. The term includes modified peptides and synthetic peptide analogues.

A T cell epitope is a short peptide derivable from a protein antigen. Antigen presenting cells can internalise antigen and process it into short fragments which are capable of binding MHC molecules. The specificity of peptide binding to the MHC depends on specific interactions between the peptide and the peptide-binding groove of the particular MHC molecule.

5

Peptides which bind to MHC class I molecules (and are recognised by CD8+ T cells) are usually between 6 and 12, more usually between 8 and 10 amino acids in length. The amino-terminal amine group of the peptide makes contact with an invariant site at one end of the peptide groove, and the carboxylate group at the carboxy terminus binds to an invariant site at the other end of the groove. The peptide lies in an extended conformation along the groove with further contacts between main-chain atoms and conserved amino acid side chains that line the groove. Variations in peptide length are accommodated by a kinking in the peptide backbone, often at proline or glycine residues.

10

Peptides which bind to MHC class II molecules are usually at least 10 amino acids, for example about 13-18 amino acids in length, and can be much longer. These peptides lie in an extended conformation along the MHC II peptide-binding groove which is open at both ends. The peptide is held in place mainly by main-chain atom contacts with conserved residues that line the peptide-binding groove.

20

The peptide of the present invention may be made using chemical methods (Peptide Chemistry, A practical Textbook. Mikos Bodansky, Springer-Verlag, Berlin.). For example, peptides can be synthesized by solid phase techniques (Roberge JY *et al* (1995) Science 269: 202-204), cleaved from the resin, and purified by preparative high performance liquid chromatography (e.g., Creighton (1983) Proteins Structures And Molecular Principles, WH Freeman and Co, New York NY). Automated synthesis may be achieved, for example, using the ABI 431A Peptide Synthesizer (Perkin Elmer) in accordance with the instructions provided by the manufacturer.

25

The peptide may alternatively be made by recombinant means, or by cleavage from a longer polypeptide. For example, the peptide may be obtained by cleavage from full-length 5T4. The composition of a peptide may be confirmed by amino acid analysis or sequencing (e.g., the Edman degradation procedure).

30

The term "peptide epitope" encompasses modified peptides. For example 5T4 peptides may be mutated, by amino acid insertion, deletion or substitution, so long as the MHC binding-specificity of the wild-type 5T4 peptide is retained. In a preferred embodiment the modified epitope has greater affinity for the peptide binding groove. Preferably the peptide contains 5
5 or fewer mutations from the wild-type sequence, more preferably 3 or fewer, most preferably 1 or 0 mutations.

Alternatively (or in addition) modifications may be made without changing the amino acid sequence of the peptide. For example, D-amino acids or other unnatural amino acids can be
10 included, the normal amide bond can be replaced by ester or alkyl backbone bonds, N-or C-alkyl substituents, side chain modifications, and constraints such as disulphide bridges and side chain amide or ester linkages can be included. Such changes may result in greater in vivo stability of the peptide, and a longer biological lifetime.

15 Modification of epitopes may be performed based on predictions for more efficient T-cell induction derived using the program "Peptide Binding Predictions" devised by K. Parker (NIH) which may be found at http://www.bimas.dcrf.nih.gov/cgi-bin/molbio/ken_parker_comboform (see also Parker, K. C *et al.* 1994.J.Immunol. 152:163).

20 A "modified" 5T4 peptide epitope includes peptides which have been bound or otherwise associated to transporter peptides or adjuvants, in order to increase their ability to elicit an immune response. For example, peptides may be fused to TAP independent transporter peptides for efficient transport to HLA and interaction with HLA molecules to enhance CTL epitopes (for review see Yewdell *et al.*, 1998 J Immunother 21:127-31; Fu *et al.*, (1998) J
25 Virol 72:1469-81).

In a further embodiment, 5T4 or 5T4 peptides may be fused to hepatitis B core antigen to enhance T helper and antibody responses (Schodel *et al.*, 1996 Intervirology 39:104-10).

30 To be an epitope, the peptide should be capable of binding to the peptide-binding groove of a MHC class I or II molecule and be recognised by a T cell.

Cell surface presentation of peptides derived from a given antigen is not random and tends to be dominated by a small number of frequently occurring epitopes. The dominance of a

particular peptide will depend on many factors, such as relative affinity for binding the MHC molecule, spatio-temporal point of generation within the APC and resistance to degradation. The epitope hierarchy for an antigen is thought to change with progression of an immune response. After a primary immune response to the immunodominant peptides, epitope
5 “spreading” may occur to sub-dominant determinants (Lehmann *et al* (1992) Nature 358:155-157).

For any given antigen, cryptic epitopes may also exist. Cryptic epitopes are those which can stimulate a T cell response when administered as a peptide but which fail to produce such a
10 response when administered as a whole antigen. It may be that during processing of the antigen into peptides in the APC the cryptic epitope is destroyed.

The peptide of the invention may be an immunodominant epitope, a sub-dominant epitope or a cryptic epitope of 5T4.
15

Epitopes for an antigen may be identified by measuring the T cell response to overlapping peptides spanning a portion of the antigen (see below) when presented by APC. Such studies usually result in “nested sets” of peptides, and the minimal epitope for a particular T cell line/clone can be assessed by measuring the response to truncated peptides.
20

The minimal epitope for an antigen may not be the best epitope for practical purposes. It may well be that amino acids flanking the minimal epitope will be required for optimal binding to the MHC.

25 *Identification of epitopes*

There are a number of methods known in the art to identify the T cell epitopes within a given antigen.

30 Naturally processed epitopes may be identified by mass spectrophotometric analysis of peptides eluted from antigen-loaded APC. These are APC that have either been encouraged to take up antigen, or have been forced to produce the protein intracellularly by transformation with the appropriate gene. Typically APC are incubated with protein either in solution or suitably targeted to the APC cell surface. After incubation at 37°C the cells are

lysed in detergent and the class II protein purified by, for example, affinity chromatography. Treatment of the purified MHC with a suitable chemical medium (for example, acid conditions) results in the elution of peptides from the MHC. This pool of peptides is separated and the profile compared with peptide from control APC treated in the same way.

5 The peaks unique to the protein expressing/fed cells are analysed (for example by mass spectrometry) and the peptide fragments identified. This procedure usually generates information about the range of peptides (usually found in "nested sets") generated from a particular antigen by antigen processing.

10 Another method for identifying epitopes is to screen a synthetic library of peptides which overlap and span the length of the antigen in an *in vitro* assay. For example, peptides which are 15 amino acids in length and which overlap by 5 or 10 amino acids may be used. The peptides are tested in an antigen presentation system which comprises antigen presenting cells and T cells. For example, the antigen presentation system may be a murine splenocyte
15 preparation, a preparation of human cells from tonsil or PBMC. Alternatively, the antigen presentation system may comprise a particular T cell line/clone and/or a particular antigen presenting cell type.

T cell activation may be measured via T cell proliferation (for example using ^3H -thymidine
20 incorporation) or cytokine production. Activation of TH1-type CD4+ T cells can, for example be detected via IFN γ production which may be detected by standard techniques, such as an ELISPOT assay.

Overlapping peptide studies usually indicate the area of the antigen in which an epitope is
25 located. The minimal epitope for a particular T cell can then be assessed by measuring the response to truncated peptides. For example if a response is obtained to the peptide comprising residues 1-15 in the overlapping library, sets which are truncated at both ends (i.e. 1-14, 1-13, 1-12 etc. and 2-15, 3-15, 4-15 etc.) can be used to identify the minimal epitope.

30 *Polyepitope string*

It has been found that a particularly effective way to induce an immune response to an antigen is by the use of a polyepitope string, which contains a plurality of antigenic epitopes from one or more antigens linked together. For example, for malaria, a polyepitope string of mainly

malaria (*P. falciparum*) CD8 T cell peptide epitopes has been described which also expresses CD4 T cell epitopes from tetanus toxoid and from the 38Kd mycobacterial antigen of various strains of *M. tuberculosis* and *M. bovis*.

- 5 The present invention also provides a polypeptide string comprising at least one peptide according to the present invention. The string may also comprise another epitope derivable from the 5T4 antigen or an epitope from another antigen – such as another TAA – or combinations thereof.
- 10 TAAs have been characterised either as membrane proteins or altered carbohydrate molecules of glycoproteins and glycolipids, however their functions remain largely unknown. One TAA family, the transmembrane 4 superfamily (TM4SF), usually has four well-conserved membrane-spanning regions, certain cysteine residues and short sequence motifs. There is evidence that TM4SF antigens exist in close association with other important membrane
- 15 receptors including CD4 and CD8 of T cells (Imai & Yoshie (1993) *J. Immunol.* 151, 6470-6481). It has also been suggested that TM4SF antigens may play a role in signal transduction which in turn, affects cell development, activation and motility. Examples of TM4SF antigens include human melanoma-associated antigen ME491, human and mouse leukocyte surface antigen CD37, and human lymphoblastic leukemia-associated TALLA-1 (Hotta, H. et al.
- 20 (1988) *Cancer Res.* 48, 2955-2962; Classon, B. J. et al. (1989) *J. Exp. Med.* 169: 1497-1502; Tomlinson, M. G. et al. (1996) *Mol. Immun.* 33: 867-872; Takagi, S. et al. (1995) *Int. J. Cancer* 61: 706-715).

- Further examples of TAAs also include, but are not limited to, TAAs in the following classes:
- 25 cancer testis antigens (HOM-MEL-40), differentiation antigens (HOM-MEL-55), overexpressed gene products (HOM-MD-21), mutated gene products (NY-COL-2), splice variants (HOM-MD-397), gene amplification products (HOM-NSCLC-11) and cancer related autoantigens (HOM-MEL-2.4) as reviewed in *Cancer Vaccines and Immunotherapy* (2000) Eds Stern, Beverley and Carroll, Cambridge University Press, Cambridge. Further examples
- 30 include, MART-1 (Melanoma Antigen Recognised by T cells-1) MAGE-A (MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A6, MAGE-A8, MAGE-A10, MAGE-A12), MAGE B (MAGE-B1- MAGE-B24), MAGE-C (MAGE-C1/CT7, CT10), GAGE (GAGE-1, GAGE-8, PAGE-1, PAGE-4, XAGE-1, XAGE-3), LAGE (LAGE-1a(1S), -1b(1L), NY-ESO-1), SSX (SSX1-SSX-5), BAGE, SCP-1, PRAME (MAPE), SART-1, SART-3, CTp11,

TSP50, CT9/BRDT, gp100, MART-1, TRP-1, TRP-2, MELAN-A/MART-1, Carcinoembryonic antigen (CEA), prostate-specific antigen (PSA), MUCIN (MUC-1) and Tyrosinase. TAAs are reviewed in Cancer Immunology (2001) Kluwer Academic Publishers, The Netherlands.

5

Cell penetrators

The present invention also provides a peptide epitope, or a polypeptide string in association with a cell penetrator.

10

Antigen presenting cells (such as dendritic cells) pulsed with peptides have proven effective in enhancing antitumour immunity (Celluzzi et al (1996) J. Exp. Med. 183 283-287; Young et al (1996) J. Exp. Med. 183 7-11). It has been shown that it is possible to prolong the presentation of a peptide by dendritic cells (and thus enhance antitumour immunity) by linking it to a cell penetrating peptide (CPP) (Wang and Wang (2002) Nature Biotechnology 20 149-154).

15

A cell penetrator may be any entity which enhances the intracellular delivery of the peptide/polypeptide string to the antigen presenting cell. For example, the cell penetrator may be a lipid which, when associated with the peptide, enhances its capacity to cross the plasma membrane. Alternatively, the cell penetrator may be a peptide. Several cell penetrating peptide (CPPs) have been identified from proteins, including the Tat protein of HIV (Frankel and Pabo (1988) Cell 55 1189-1193), the VP22 protein of HSV (Elliott and O'Hare (1997) Cell 88 223-233) and fibroblast growth factor (Lin et al (1995) J. Biol. Chem. 270 14255-14258).

25

The term "associated with" is intended to include direct linkage, for example by a covalent bond. Examples of covalent bonds for linking amino acids include disulphide bridges and peptide bonds. In a preferred embodiment, the peptide/polypeptide string and a CPP are linked by a peptide bond to create a fusion protein.

30

The term also includes non-covalent linkage, such as association by electrostatic bonding, hydrogen bonding and van der Waals forces. The cell penetrator and peptide/polypeptide

string may be associated without covalent or non-covalent bonding. For example the cell penetrator may be a lipid which encapsulates the peptide/polypeptide string (e.g. a liposome).

5T4

5

5T4 has been previously characterised, for example, in WO89/07947. The sequence of human 5T4 which appears in GenBank at accession no. Z29083. The peptide may also be derived from a 5T4 antigen from a different species, such as murine 5T4 (WO00/29428), canine 5T4 (WO01/36486) or feline 5T4 (SEQ ID No 1 presented herein). The peptide may also be derived from a naturally occurring variant of 5T4 found with a particular species, preferably a mammal. Such a variant may be encoded by a related gene of the same gene family, by an allelic variant of a particular gene, or represent an alternative splicing variant of the 5T4 gene.

10

15

A peptide derived from 5T4 from a different species or a splice variant may have a different amino acid sequence from the analogous human wild-type 5T4 peptide. However, as long as the peptide retains the same qualitative binding specificity as the human peptide (i.e. it binds in the peptide binding groove of an MHC molecule of the same haplotype) then it is still an epitope in accordance with the present invention.

20

Nucleic acid

The present invention also relates to a nucleic acid sequence capable of encoding a peptide epitope or polypeptide string according to the first aspect of the invention.

25

A "nucleic acid", as referred to herein, may be DNA or RNA, naturally-occurring or synthetic, or any combination thereof. Nucleic acids according to the invention are limited only in that they serve the function of encoding a 5T4 peptide in such a way that it may be translated by the machinery of the cells of a host organism. Thus, natural nucleic acids may be modified, for example to increase the stability thereof. DNA and/or RNA, but especially RNA, may be modified in order to improve nuclease resistance of the members. For example, known modifications for ribonucleotides include 2'-O-methyl, 2'-fluoro, 2'-NH₂, and 2'-O-allyl. The modified nucleic acids according to the invention may comprise chemical modifications which have been made in order to increase the *in vivo* stability of the nucleic

30

acid, enhance or mediate the delivery thereof, or reduce the clearance rate from the body. Examples of such modifications include chemical substitutions at the ribose and/or phosphate and/or base positions of a given RNA sequence. See, for example, WO 92/03568; U.S. 5,118,672; Hobbs *et al.*, (1973) *Biochemistry* 12:5138; Guschlbauer *et al.*, (1977) *Nucleic*
5 *Acids Res.* 4:1933; Schibaharu *et al.*, (1987) *Nucleic Acids Res.* 15:4403; Pieken *et al.*, (1991) *Science* 253:314, each of which is specifically incorporated herein by reference.

The present invention also encompasses nucleic acids which will hybridise to a nucleic acid sequence capable of encoding a peptide epitope or polypeptide string according to the first
10 aspect of the invention.

Stringency of hybridisation refers to conditions under which polynucleic acid hybrids are stable. Such conditions are evident to those of ordinary skill in the field. As known to those of skill in the art, the stability of hybrids is reflected in the melting temperature (T_m) of the
15 hybrid which decreases approximately 1 to 1.5°C with every 1% decrease in sequence homology. In general, the stability of a hybrid is a function of sodium ion concentration and temperature. Typically, the hybridisation reaction is performed under conditions of higher stringency, followed by washes of varying stringency.

20 As used herein, high stringency refers to conditions that permit hybridisation of only those nucleic acid sequences that form stable hybrids in 1 M Na^+ at 65-68 °C. High stringency conditions can be provided, for example, by hybridisation in an aqueous solution containing 6x SSC, 5x Denhardt's, 1 % SDS (sodium dodecyl sulphate), 0.1 Na^+ pyrophosphate and 0.1 mg/ml denatured salmon sperm DNA as non specific competitor. Following hybridisation,
25 high stringency washing may be done in several steps, with a final wash (about 30 min) at the hybridisation temperature in 0.2 - 0.1x SSC, 0.1 % SDS.

Moderate stringency refers to conditions equivalent to hybridisation in the above described solution but at about 60-62°C. In that case the final wash is performed at the hybridisation
30 temperature in 1x SSC, 0.1 % SDS.

Low stringency refers to conditions equivalent to hybridisation in the above described solution at about 50-52°C. In that case, the final wash is performed at the hybridisation temperature in 2x SSC, 0.1 % SDS.

It is understood that these conditions may be adapted and duplicated using a variety of buffers, e.g. formamide-based buffers, and temperatures. Denhardt's solution and SSC are well known to those of skill in the art as are other suitable hybridisation buffers (see, e.g. Sambrook, *et al.*, eds. (1989) *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, New York or Ausubel, *et al.*, eds. (1990) *Current Protocols in Molecular Biology*, John Wiley & Sons, Inc.). Optimal hybridisation conditions have to be determined empirically, as the length and the GC content of the probe also play a role.

Given the guidance provided herein, the nucleic acids of the invention are obtainable according to methods well known in the art. For example, a DNA of the invention is obtainable by chemical synthesis, using polymerase chain reaction (PCR) or direct cleavage from a longer polynucleotide, such as the entire 5T4 coding sequence or a fragment thereof.

Chemical methods for synthesis of a nucleic acid of interest are known in the art and include triester, phosphite, phosphoramidite and H-phosphonate methods, PCR and other autoprimer methods as well as oligonucleotide synthesis on solid supports. These methods may be used if the entire nucleic acid sequence of the nucleic acid is known, or the sequence of the nucleic acid complementary to the coding strand is available. Alternatively, if the target amino acid sequence is known, one may infer potential nucleic acid sequences using known and preferred coding residues for each amino acid residue.

It is envisaged that the nucleic acid of the invention can be modified by nucleotide substitution, nucleotide deletion, nucleotide insertion or inversion of a nucleotide stretch, and any combination thereof. Such mutants can be used e.g. to produce a 5T4 peptide that has an amino acid sequence differing from the wild-type 5T4 epitope. Such a peptide is still a peptide in accordance with the present invention if it retains the capacity to act as a T cell epitope. Mutagenesis may be predetermined (site-specific) or random. A mutation which is not a silent mutation should not place sequences out of reading frames and preferably will not create complementary regions that could hybridise to produce secondary mRNA structure such as loops or hairpins.

Variants/fragments/homologues/derivatives

The present invention encompasses the use of nucleotide and amino acid sequences and variants, homologues, derivatives and fragments thereof.

The term "variant" is used to mean a naturally occurring polypeptide or nucleotide sequence
5 which differs from a wild-type sequence.

The term "fragment" indicates that a polypeptide or nucleotide sequence comprises a fraction of a subject sequence. Preferably the sequence comprises at least 50%, more preferably at least 65%, more preferably at least 80%, more preferably at least 90%, most preferably at
10 least 90% of the subject sequence. If the fragment is a fragment of an amino acid then preferably the fragments are 6-12 amino acids in length. More preferably, the fragments are 8, 9 or 10 amino acids in length. By way of example, SEQ ID No. 5 and SEQ ID No. 7 are fragments of SEQ ID No. 3; SEQ ID No. 6 is a fragment of SEQ ID No. 4

15 The term "homologue" means an entity having a certain homology with the subject amino acid sequences and the subject nucleotide sequences. Here, the term "homology" can be equated with "identity".

In the present context, a homologous sequence is taken to include an amino acid sequence,
20 which may be at least 75, 85 or 90 % identical, preferably at least 95 or 98 % identical to the subject sequence. Typically, the homologues will comprise the same activity as the subject amino acid sequence. Although homology can also be considered in terms of similarity (i.e. amino acid residues having similar chemical properties/functions), in the context of the present invention it is preferred to express homology in terms of sequence identity.

25 In the present context, a homologous sequence is taken to include a nucleotide sequence, which may be at least 75, 85 or 90% identical, preferably at least 95 or 98 % identical to the subject sequence. Typically, the homologues will comprise the same activity as the subject sequence. Although homology can also be considered in terms of similarity (i.e. amino acid
30 residues having similar chemical properties/functions), in the context of the present invention it is preferred to express homology in terms of sequence identity.

Homology comparisons may be conducted by eye, or more usually, with the aid of readily available sequence comparison programs. These commercially available computer programs can calculate % homology between two or more sequences.

5 % homology may be calculated over contiguous sequences, i.e. one sequence is aligned with the other sequence and each amino acid in one sequence is directly compared with the corresponding amino acid in the other sequence, one residue at a time. This is called an "ungapped" alignment. Typically, such ungapped alignments are performed only over a relatively short number of residues.

10

Although this is a very simple and consistent method, it fails to take into consideration that, for example, in an otherwise identical pair of sequences, one insertion or deletion will cause the following amino acid residues to be put out of alignment, thus potentially resulting in a large reduction in % homology when a global alignment is performed. Consequently, most sequence comparison methods are designed to produce optimal alignments that take into
15 consideration possible insertions and deletions without penalising unduly the overall homology score. This is achieved by inserting "gaps" in the sequence alignment to try to maximise local homology.

20 However, these more complex methods assign "gap penalties" to each gap that occurs in the alignment so that, for the same number of identical amino acids, a sequence alignment with as few gaps as possible - reflecting higher relatedness between the two compared sequences - will achieve a higher score than one with many gaps. "Affine gap costs" are typically used that charge a relatively high cost for the existence of a gap and a smaller penalty for each
25 subsequent residue in the gap. This is the most commonly used gap scoring system. High gap penalties will of course produce optimised alignments with fewer gaps. Most alignment programs allow the gap penalties to be modified. However, it is preferred to use the default values when using such software for sequence comparisons. For example, when using the GCG Wisconsin Bestfit package the default gap penalty for amino acid sequences is -12 for a
30 gap and -4 for each extension.

Calculation of maximum % homology therefore firstly requires the production of an optimal alignment, taking into consideration gap penalties. A suitable computer program for carrying out such an alignment is the GCG Wisconsin Bestfit package (University of Wisconsin,

U.S.A.; Devereux et al., 1984, *Nucleic Acids Research* 12:387). Examples of other software than can perform sequence comparisons include, but are not limited to, the BLAST package (see Ausubel et al., 1999 *ibid* – Chapter 18), FASTA (Atschul et al., 1990, *J. Mol. Biol.*, 403-410) and the GENEWORKS suite of comparison tools. Both BLAST and FASTA are
5 available for offline and online searching (see Ausubel et al., 1999 *ibid*, pages 7-58 to 7-60). However, for some applications, it is preferred to use the GCG Bestfit program. A new tool, called BLAST 2 Sequences is also available for comparing protein and nucleotide sequence (see *FEMS Microbiol Lett* 1999 174(2): 247-50; *FEMS Microbiol Lett* 1999 177(1): 187-8).

10 Although the final % homology can be measured in terms of identity, the alignment process itself is typically not based on an all-or-nothing pair comparison. Instead, a scaled similarity score matrix is generally used that assigns scores to each pairwise comparison based on chemical similarity or evolutionary distance. An example of such a matrix commonly used is the BLOSUM62 matrix - the default matrix for the BLAST suite of programs. GCG
15 Wisconsin programs generally use either the public default values or a custom symbol comparison table if supplied (see user manual for further details). For some applications, it is preferred to use the public default values for the GCG package, or in the case of other software, the default matrix - such as BLOSUM62.

20 Once the software has produced an optimal alignment, it is possible to calculate % homology, preferably % sequence identity. The software typically does this as part of the sequence comparison and generates a numerical result.

The sequences may also have deletions, insertions or substitutions of amino acid residues,
25 which produce a silent change and result in a functionally equivalent substance. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues as long as the secondary binding activity of the substance is retained. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include
30 lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values include leucine, isoleucine, valine, glycine, alanine, asparagine, glutamine, serine, threonine, phenylalanine, and tyrosine.

Conservative substitutions may be made, for example, according to the Table below. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other:

ALIPHATIC	Non-polar	G A P
		I L V
	Polar - uncharged	C S T M
		N Q
	Polar - charged	D E
		K R
AROMATIC		H F W Y

5

The present invention also encompasses homologous substitution (substitution and replacement are both used herein to mean the interchange of an existing amino acid residue, with an alternative residue) may occur i.e. like-for-like substitution - such as basic for basic, acidic for acidic, polar for polar etc. Non-homologous substitution may also occur i.e. from one class of residue to another or alternatively involving the inclusion of unnatural amino acids - such as ornithine (hereinafter referred to as Z), diaminobutyric acid ornithine (hereinafter referred to as B), norleucine ornithine (hereinafter referred to as O), pyriylalanine, thienylalanine, naphthylalanine and phenylglycine.

15 Replacements may also be made by unnatural amino acids include; alpha* and alpha-disubstituted* amino acids, N-alkyl amino acids*, lactic acid*, halide derivatives of natural amino acids - such as trifluorotyrosine*, p-Cl-phenylalanine*, p-Br-phenylalanine*, p-I-phenylalanine*, L-allyl-glycine*, β -alanine*, L- α -amino butyric acid*, L- γ -amino butyric acid*, L- α -amino isobutyric acid*, L- ϵ -amino caproic acid[#], 7-amino heptanoic acid*, L-methionine sulfone^{#*}, L-norleucine*, L-norvaline*, p-nitro-L-phenylalanine*, L-hydroxyproline[#], L-thioprolin*, methyl derivatives of phenylalanine (Phe) - such as 4-methyl-Phe*, pentamethyl-Phe*, L-Phe (4-amino)[#], L-Tyr (methyl)*, L-Phe (4-isopropyl)*, L-Tic (1,2,3,4-tetrahydroisoquinoline-3-carboxyl acid)*, L-diaminopropionic acid[#] and L-Phe (4-benzyl)*. The notation * has been utilised for the purpose of the discussion above (relating to homologous or non-homologous substitution), to indicate the hydrophobic nature of the derivative whereas # has been utilised to indicate the hydrophilic nature of the derivative, #*

20

25

indicates amphipathic characteristics.

Variant amino acid sequences may include suitable spacer groups that may be inserted between any two amino acid residues of the sequence including alkyl groups - such as methyl, ethyl or propyl groups - in addition to amino acid spacers - such as glycine or β -alanine residues. A further form of variation involves the presence of one or more amino acid residues in peptoid form will be well understood by those skilled in the art. For the avoidance of doubt, "the peptoid form" is used to refer to variant amino acid residues wherein the α -carbon substituent group is on the residue's nitrogen atom rather than the α -carbon. Processes for preparing peptides in the peptoid form are known in the art, for example, Simon RJ et al., PNAS (1992) 89(20), 9367-9371 and Horwell DC, Trends Biotechnol. (1995) 13(4), 132-134.

The nucleotide sequences for use in the present invention may include within them synthetic or modified nucleotides. A number of different types of modification to oligonucleotides are known in the art. These include methylphosphonate and phosphorothioate backbones and/or the addition of acridine or polylysine chains at the 3' and/or 5' ends of the molecule. For the purposes of the present invention, it is to be understood that the nucleotide sequences may be modified by any method available in the art. Such modifications may be carried out to enhance the in vivo activity or life span of nucleotide sequences useful in the present invention.

Vector system

The nucleic acid sequence of the present invention may be delivered to a cell by way of a vector system.

As used herein, a "vector" may be any agent capable of delivering or maintaining nucleic acid in a host cell, and includes viral vectors, plasmids, naked nucleic acids, nucleic acids complexed with polypeptide or other molecules and nucleic acids immobilised onto solid phase particles. Such vectors are described in detail below. It will be understood that the present invention, in its broadest form, is not limited to any specific vector for delivery of the 5T4 peptide-encoding nucleic acid.

The vector may be a prokaryotic or eukaryotic vector.

Nucleic acids encoding 5T4 epitopes and polypeptide strings in accordance with the present
5 invention can be delivered by viral or non-viral techniques.

Non-viral delivery systems include but are not limited to DNA transfection methods. Here, transfection includes a process using a non-viral vector to deliver a 5T4 gene to a target mammalian cell.

10

Typical transfection methods include electroporation, nucleic acid biolistics, lipid-mediated transfection, compacted nucleic acid-mediated transfection, liposomes, immunoliposomes, lipofectin, cationic agent-mediated, cationic facial amphiphiles (CFAs) (Nature Biotechnology 1996 14; 556), multivalent cations such as spermine, cationic lipids or
15 polylysine, 1, 2-bis (oleoyloxy)-3-(trimethylammonio) propane (DOTAP)-cholesterol complexes (Wolff and Trubetskoy 1998 Nature Biotechnology 16: 421) and combinations thereof.

Non-viral delivery systems may also include, but are not limited to, bacterial delivery
20 systems. The use of bacteria as anticancer agents and as delivery agents for anticancer drugs has been reviewed in Expert Opin Biol Ther 2001 Mar;1(2):291-300.

Suitable bacteria include, but are not limited to, bacterial pathogens and non-pathogenic commensal bacteria. By way of example, suitable genera may be selected from Salmonella,
25 Mycobacterium, Yersinia, Shigella, Listeria and Brucella. Recent advances in the pathogenesis and molecular biology of these bacteria have allowed the rational development of new and improved bacterial carriers and more effective gene expression systems. These advances have improved the performance and versatility of these delivery systems.

30 The bacteria may be invasive intracellular bacteria that are able to transfer eukaryotic expression plasmids into mammalian host cells *in vitro* and *in vivo*. Plasmid transfer may take place when the recombinant bacterium dies within the host cell, either due to metabolic attenuation or induction of autolysis. Alternatively, antibiotics may be used and spontaneous transfer has also been observed, indicating that this phenomenon might also occur under

physiological conditions. Plasmid transfer has been reported for *Shigella flexneri*, *Salmonella typhimurium*, *S. typhi*, *Listeria monocytogenes* and recombinant *Escherichia coli*, but other invasive bacteria may also be used.

- 5 Bacteria may be used for DNA vaccine delivery. Such bacteria may enter the host cell cytosol after phagocytosis, for example, *Shigella* and *Listeria*, or they remain in the phagosomal compartment - such as *Salmonella*. Both intracellular localisations may be suitable for successful delivery of DNA vaccine vectors.
- 10 The bacterial delivery systems may utilise *Mycobacterium* in the form of non pathogenic *Mycobacterium* strains, genetic transfer systems in the form of cloning and expression vectors, and related technologies to provide products containing, for example, non toxic immuno-regulating *Mycobacterium* adjuvants, non toxic immuno-stimulating exogenous antigens specific for a variety of diseases, and non toxic amounts of cytokines that boost the
- 15 TH-1 pathway (Tunis Med 2001 Feb;79(2):65-81).

- Salmonella strains – such as attenuated strains - which comprise defined gene deletions, may be used as suitable delivery systems – such as the delivery of antigens. A number of strategies for delivery by these strains have been attempted, ranging from plasmid-based to
- 20 chromosomal integration systems. By way of example, Rosenkranz et al. Vaccine 2003, 21(7-8), 798-801 describe eukaryotic expression plasmids encoding cytokines, and assessed their capacity to modulate immune responses in different experimental models. Plasmids encoding mouse IL-4 and IL-18 under cytomegalovirus promoter were constructed and transformed into live attenuated *Salmonella enterica* serovar Typhi strain CVD 908-htrA, and
- 25 *Salmonella enterica* serovar Typhimurium strain SL3261.

The use of attenuated *Salmonella typhimurium* as a potential gene delivery vector has been reviewed in Anticancer Res 2002, 22(6A):3261-6.

- 30 *Brucella abortus* may also be used as a suitable delivery system as described by Vemulapalli et al. Infect Immun (2000) 68(6):3290-6. *Brucella abortus* strain RB51 is a stable, rough, attenuated mutant widely used as a live vaccine for bovine brucellosis. This strain may be used as a delivery vector, for example, in the delivery of protective antigens of other

intracellular pathogens to which the induction of a strong Th1 type of immune response is needed for effective protection.

Boyd *et al.* Eur J Cell Biol (2000) 79 (10) 659-71 describe the use of *Yersinia enterocolitica* for the delivery of proteins into a wide range of cell types. *Y. enterocolitica* translocates virulence proteins, called Yop effectors, into the cytosol of eukaryotic cells. No limit to the range of eukaryotic cells into which *Y. enterocolitica* can translocate Yops was reported. The Yop effectors YopE, YopH and YopT were each cytotoxic for the adherent cell types tested, showing that not only is *Y. enterocolitica* not selective in its translocation of particular Yop effectors into each cell type, but also that the action of these Yop effectors is not cell type specific. To use the Yersinia translocation system for broad applications, a *Y. enterocolitica* translocation strain and vector for the delivery of heterologous proteins into eukaryotic cells was constructed. This strain and vector combination lacks the translocated Yop effectors and allows delivery into eukaryotic cells of heterologous proteins fused to the minimal N-terminal secretion/translocation signal of YopE.

US 5965381 describes a recombinant Yersinia for the delivery of proteins into eukaryotic cells. Such Yersinia are deficient in the production of functional effector proteins, but are endowed with a functional secretion and translocation system.

Cell adhesion molecules are a large group of molecules involved in a variety of cell-to-cell and cell-to-extra-cellular matrix (ECM) interactions and are exploited by a number of pathogenic micro-organisms as receptors for cell entry. These molecules may be used for the targeting and uptake of both gene and drug delivery systems. Cell adhesion molecules and their use in gene transfer has been reviewed in Adv Drug Deliv Rev 2000 Nov 15;44(2-3):135-52.

The gene gun delivery system may also be used for the delivery of DNA, which is a highly reliable method compared to intramuscular inoculation (Jpn J Pharmacol 2000 Jul;83(3):167-74).

Viral delivery systems include but are not limited to adenovirus vectors, adeno-associated viral (AAV) vectors, herpes viral vectors, retroviral vectors, lentiviral vectors or baculoviral vectors, venezuelan equine encephalitis virus (VEE), poxviruses such as: canarypox virus

(Taylor *et al* 1995 Vaccine 13:539-549), entomopox virus (Li Y *et al* 1998 XIIth International Poxvirus Symposium p144. Abstract), penguin pox (Standard *et al.* J Gen Virol. 1998 79:1637-46) alphavirus, and alphavirus based DNA vectors.

- 5 Examples of retroviruses include but are not limited to: murine leukaemia virus (MLV), human immunodeficiency virus (HIV), equine infectious anaemia virus (EIAV), mouse mammary tumour virus (MMTV), Rous sarcoma virus (RSV), Fujinami sarcoma virus (FuSV), Moloney murine leukaemia virus (Mo-MLV), FBR murine osteosarcoma virus (FBR MSV), Moloney murine sarcoma virus (Mo-MSV), Abelson murine leukaemia virus (A-
10 MLV), Avian myelocytomatosis virus-29 (MC29), and Avian erythroblastosis virus (AEV).

A detailed list of retroviruses may be found in Coffin *et al* ("Retroviruses" 1997 Cold Spring Harbour Laboratory Press Eds: JM Coffin, SM Hughes, HE Varmus pp 758-763).

- 15 Lentiviruses can be divided into primate and non-primate groups. Examples of primate lentiviruses include but are not limited to: the human immunodeficiency virus (HIV), the causative agent of human auto-immunodeficiency syndrome (AIDS), and the simian immunodeficiency virus (SIV). The non-primate lentiviral group includes the prototype "slow virus" visna/maedi virus (VMV), as well as the related caprine arthritis-encephalitis
20 virus (CAEV), equine infectious anaemia virus (EIAV) and the more recently described feline immunodeficiency virus (FIV) and bovine immunodeficiency virus (BIV).

- A distinction between the lentivirus family and other types of retroviruses is that lentiviruses have the capability to infect both dividing and non-dividing cells (Lewis *et al* 1992 EMBO. J
25 11: 3053-3058; Lewis and Emerman 1994 J. Virol. 68: 510-516). In contrast, other retroviruses - such as MLV - are unable to infect non-dividing cells such as those that make up, for example, muscle, brain, lung and liver tissue.

- The vector of the present invention may be configured as a split-intron vector. A split intron
30 vector is described in PCT patent applications WO 99/15683 and WO 99/15684.

If the features of adenoviruses are combined with the genetic stability of retroviruses/lentiviruses then essentially the adenovirus can be used to transduce target cells to become transient retroviral producer cells that could stably infect neighbouring cells. Such

retroviral producer cells engineered to express 5T4 antigen can be implanted in organisms such as animals or humans for use in the treatment of angiogenesis and/or cancer.

The vector of the present invention may be configured as a pseudotyped vector.

5

In the design of retroviral vectors it may be desirable to engineer particles with different target cell specificities to the native virus, to enable the delivery of genetic material to an expanded or altered range of cell types. One manner in which to achieve this is by engineering the virus envelope protein to alter its specificity. Another approach is to introduce a heterologous envelope protein into the vector particle to replace or add to the native envelope protein of the virus.

10

The term pseudotyping means incorporating in at least a part of, or substituting a part of, or replacing all of, an *env* gene of a viral genome with a heterologous *env* gene, for example an *env* gene from another virus. Pseudotyping is not a new phenomenon and examples may be found in WO 99/61639, WO-A-98/05759, WO-A-98/05754, WO-A-97/17457, WO-A-96/09400, WO-A-91/00047 and Mebatsion *et al* 1997 Cell 90, 841-847.

15

Pseudotyping can improve retroviral vector stability and transduction efficiency. A pseudotype of murine leukemia virus packaged with lymphocytic choriomeningitis virus (LCMV) has been described (Miletic *et al* (1999) J. Virol. 73:6114-6116) and shown to be stable during ultracentrifugation and capable of infecting several cell lines from different species.

20

25 *Poxvirus Vectors*

TAAAs are weakly immunogenic, being recognised as "self" by the immune system and thus tolerated to a large extent. The use of poxvirus vectors is sometimes able to cause the antigens to be presented such that this tolerance may be overcome at least in part, (especially if immune evasion genes are deleted - see below) thus enabling a host to raise an immune response.

30

Poxvirus vectors are preferred for use in the present invention. Pox viruses are engineered for recombinant gene expression and for the use as recombinant live vaccines. This entails the

use of recombinant techniques to introduce nucleic acids encoding foreign antigens into the genome of the pox virus. If the nucleic acid is integrated at a site in the viral DNA which is non-essential for the life cycle of the virus, it is possible for the newly produced recombinant pox virus to be infectious, that is to say to infect foreign cells and thus to express the integrated DNA sequence. The recombinant pox virus prepared in this way can be used as live vaccines for the prophylaxis and/or treatment of pathologic and infectious disease.

Expression of 5T4 peptide(s) in recombinant pox viruses, such as vaccinia viruses, requires the ligation of vaccinia promoters to the nucleic acid encoding the 5T4 peptide(s). Plasmid vectors (also called insertion vectors), have been constructed to insert nucleic acids into vaccinia virus through homologous recombination between the viral sequences flanking the nucleic acid in a donor plasmid and homologous sequence present in the parental virus (Mackett *et al* 1982 PNAS 79: 7415-7419). One type of insertion vector is composed of: (a) a vaccinia virus promoter including the transcriptional initiation site; (b) several unique restriction endonuclease cloning sites located downstream from the transcriptional start site for insertion of nucleic acid; (c) nonessential vaccinia virus sequences (such as the Thymidine Kinase (*TK*) gene) flanking the promoter and cloning sites which direct insertion of the nucleic acid into the homologous nonessential region of the virus genome; and (d) a bacterial origin of replication and antibiotic resistance marker for replication and selection in *E. Coli*. Examples of such vectors are described by Mackett (Mackett *et al* 1984, J. Virol. 49: 857-864).

The isolated plasmid containing the nucleic acid to be inserted is transfected into a cell culture, e.g., chick embryo fibroblasts, along with the parental virus, e.g., poxvirus. Recombination between homologous pox DNA in the plasmid and the viral genome respectively results in a recombinant poxvirus modified by the presence of the promoter-gene construct in its genome, at a site which does not affect virus viability.

As noted above, the nucleic acid is inserted into a region (insertion region) in the virus which does not affect virus viability of the resultant recombinant virus. Such regions can be readily identified in a virus by, for example, randomly testing segments of virus DNA for regions that allow recombinant formation without seriously affecting virus viability of the recombinant. One region that can readily be used and is present in many viruses is the thymidine kinase (TK) gene. For example, the TK gene has been found in all pox virus genomes examined

[leporipoxvirus: Upton, *et al* J. Virology 60:920 (1986) (sheep fibroma virus); capripoxvirus: Gershon, *et al* J. Gen. Virol. 70:525 (1989) (Kenya sheep-1); orthopoxvirus: Weir, *et al* J. Virol 46:530 (1983) (vaccinia); Esposito, *et al* Virology 135:561 (1984) (monkeypox and variola virus); Hruby, *et al* PNAS, 80:3411 (1983) (vaccinia); Kilpatrick, *et al* Virology 143:399 (1985) (Yaba monkey tumour virus); avipoxvirus: Binns, *et al* J. Gen. Virol 69:1275 (1988) (fowlpox); Boyle, *et al* Virology 156:355 (1987) (fowlpox); Schnitzlein, *et al* J. Virological Method, 20:341 (1988) (fowlpox, quailpox); entomopox (Lytvyn, *et al* J. Gen. Virol 73:3235-3240 (1992)).

- 10 In vaccinia, in addition to the TK region, other insertion regions include, for example, HindIII M.

In fowlpox, in addition to the TK region, other insertion regions include, for example, BamHI J [Jenkins, *et al* AIDS Research and Human Retroviruses 7:991-998 (1991)] the EcoRI-HindIII fragment, BamHI fragment, EcoRV-HindIII fragment, BamHI fragment and the HindIII fragment set forth in EPO Application No. 0 308 220 A1. [Calvert, *et al* J. of Virol 67:3069-3076 (1993); Taylor, *et al* Vaccine 6:497-503 (1988); Spehner, *et al* (1990) and Boursnell, *et al* J. of Gen. Virol 71:621-628 (1990)].

- 20 In swinepox preferred insertion sites include the thymidine kinase gene region.

A promoter can readily be selected depending on the host and the target cell type. For example in poxviruses, pox viral promoters should be used, such as the vaccinia 7.5K, or 40K or fowlpox C1. Artificial constructs containing appropriate pox sequences can also be used.

25 Enhancer elements can also be used in combination to increase the level of expression. Furthermore, the use of inducible promoters, which are also well known in the art, are preferred in some embodiments.

Foreign gene expression can be detected by enzymatic or immunological assays (for example, immuno-precipitation, radioimmunoassay, or immunoblotting). Naturally occurring membrane glycoproteins produced from recombinant vaccinia infected cells are glycosylated and may be transported to the cell surface. High expressing levels can be obtained by using strong promoters.

30

Other requirements for viral vectors for use in vaccines include good immunogenicity and safety. MVA is a replication-impaired vaccinia strain with a good safety record. In most cell types and normal human tissue, MVA does not replicate. Replication of MVA is observed in a few transformed cell types such as BHK21 cells. Carroll *et al* (1997) have shown that the recombinant MVA is equally as good as conventional recombinant vaccinia vectors at generating a protective CD8+T cell response and is an efficacious alternative to the more commonly used replication competent vaccinia virus. The vaccinia virus strains derived from MVA, or independently developed strains having the features of MVA which make MVA particularly suitable for use in a vaccine, are also suitable for use in the present invention.

Preferably, the vector is a vaccinia virus vector such as MVA or NYVAC. Most preferred is the vaccinia strain modified virus ankara (MVA) or a strain derived therefrom. Alternatives to vaccinia vectors include avipox vectors such as fowlpox or canarypox known as ALVAC and strains derived therefrom which can infect and express recombinant proteins in human cells but are unable to replicate.

In one aspect of the present invention at least one immune evasion gene is deleted from the poxvirus vector.

Viruses, especially large viruses such as poxviruses which have an extensive coding capacity and can thus encode a variety of genes, have developed a number of techniques for evading the immune system of their hosts. For example, they are able to evade non-specific defences such as complement, interferons and the inflammatory response, as well as to interfere with or block the function of cytokines. A number of these immune evasion polypeptides have been deleted from MVA, with the exception of the interferon resistance protein in the left terminal region.

Poxviruses in general, being large DNA viruses which establish acute, rather than latent, infections. They encode so many antigenic proteins that antigenic variation is difficult, thus relying on active immune evasion to protect themselves from the mammalian immune system. They possess a number of genes which encode polypeptides which are responsible for interfering with a number of aspects of the immune system: they disrupt interferon action, interfere with complement, cytokine activity, inflammatory responses and CTL recognition (for a review, Smith *et al.*, (1997) Immunol Rev 159:137-154). Removal of these proteins is

beneficial in promoting the ability of weak immunogens encoded on a poxvirus vector to elicit an immune response in a subject.

5 An immune evasion gene or polypeptide is a gene, or its product, which assists the virus in evading the mammalian immune system. Preferably, the gene or gene product interferes with the working of the immune system, at least one level. This may be achieved in a number of ways, such as by interfering in signalling pathways by providing competitors for signalling molecules, by providing soluble cytokine receptor mimics and the like.

10 Immune evasion genes include, but are not limited to, the following:

Interferon evasion genes. Vaccinia possesses at least three genes which interfere with IFN action. The E3L gene expresses a 25Kd polypeptide which competes with P1 protein kinase for binding to dsRNA, an event which leads to activation of P1, phosphorylation of eIF2 α and
15 resultant failure of translation initiation complex assembly. This pathway is ordinarily responsive to IFN activation, but is impeded by E3L expression thus allowing translation initiation to proceed unimpeded.

The K3L gene expresses a 10.5Kd polypeptide which also interferes with P1 activity, since it
20 is effectively an eIF2 mimic and acts as a competitor for P1 protein kinase. Its mode of action is thus similar to E3L.

The A18R gene is predicted to encode a helicase, which appears to interfere with the 2',5'-oligoadenylate pathway, which is in turn IFN responsive. 2',5'-A activates RNase L, which
25 acts to prevent viral translation. Expression of A18R appears to reduce 2',5'-A levels in infected cells.

Complement. The product of the B5R gene of vaccinia is known to be highly related to factor H, a regulator of the alternative complement pathway. This pathway may be activated by
30 antigen alone, unlike the classical pathway. The B5R gene product thus may interfere with the alternative complement pathway.

The C21L gene is in turn related to C4b-binding protein in humans, and interacts with cells bearing C4b on the surface to prevent binding to the CR1 complement receptor.

Soluble Cytokine Receptors. The product of the vaccinia WR B15R gene (B16R in Copenhagen strain vaccinia) is related to IL1-R.

- 5 The WR gene ORF SaIF19R, A53R in Copenhagen strain vaccinia, encodes a TNF receptor. However, in wild-type virus both of these genes are believed to be inactive due to fragmentation of the ORFs.

- The B8R gene is believed to encode a soluble IFN- γ receptor, providing the virus with yet
10 another IFN evasion mechanism.

Inflammation. A number of genes are believed to be involved in the prevention of inflammatory responses to viral infection. These include A44L, K2L, B13R and B22R.

- 15 In one aspect of the present invention, the majority of the immune evasion genes are deleted from the recombinant poxvirus vector. Preferably, all the immune evasion genes are deleted. Thus, in one aspect of the present invention, the recombinant poxvirus vector is a recombinant MVA vector in which the K3L interferon resistance protein gene has been disrupted or deleted.

20

- Preferred are poxviruses which are non-hazardous to the intended subject. Thus, for example, for use in humans, poxviruses which are either host-range restricted, such as avipox viruses, or otherwise attenuated, such as attenuated strains of vaccinia (including NYVAC and MVA) are preferred. Most preferred are attenuated vaccinia virus strains, although non-vaccinia
25 strains are usefully employed in subjects with pre-existing smallpox immunity.

- A construct which contains at least one nucleic acid which codes for 5T4 epitope(s) flanked by MVA DNA sequences adjacent to a naturally occurring deletion, e.g. deletion II, within the MVA genome, is introduced into cells infected with MVA, to allow homologous
30 recombination.

Once the construct has been introduced into the eukaryotic cell and the 5T4 epitope DNA has recombined with the viral DNA, the desired recombinant vaccinia virus, can be isolated, preferably with the aid of a marker (Nakano *et al* Proc. Natl. Acad. Sci. USA 79, 1593-1596

[1982], Franke *et al* Mol. Cell. Biol. 1918-1924 [1985], Chakrabarti *et al* Mol. Cell. Biol. 3403-3409 [1985], Fathi *et al* Virology 97-105 [1986]).

5 The construct to be inserted can be linear or circular. A circular DNA is preferred, especially a plasmid. The construct contains sequences flanking the left and the right side of a naturally occurring deletion, c.g. deletion II, within the MVA genome (Altenburger, W., Suter, C.P. and Altenburger J. (1989) Arch. Virol. 105, 15-27). The foreign DNA sequence is inserted between the sequences flanking the naturally occurring deletion.

10 For the expression of at least one nucleic acid, it is necessary for regulatory sequences, which are required for the transcription of the nucleic acid to be present upstream of the nucleic acid. Such regulatory sequences are known to those skilled in the art, and includes for example those of the vaccinia 11 kDa gene as are described in EP-A-198,328, and those of the 7.5 kDa gene (EP-A-110,385).

15 The construct can be introduced into the MVA infected cells by transfection, for example by means of calcium phosphate precipitation (Graham *et al* Virol. 52, 456-467 [1973; Wigler *et al* Cell 777-785 [1979] by means of electroporation (Neumann *et al* EMBO J. 1, 841-845 [1982]), by microinjection (Graessmann *et al* Meth. Enzymology 101, 482-492 (1983)), by
20 means of liposomes (Straubinger *et al* Methods in Enzymology 101, 512-527 (1983)), by means of spheroplasts (Schaffner, Proc. Natl. Acad. Sci. USA 77, 2163-2167 (1980)) or by other methods known to those skilled in the art. Transfection by means of liposomes is preferred.

25 The recombinant priming and boosting vectors of the present invention can have a tropism for a specific cell type in the mammal. By way of example, the recombinant vectors of the present invention can be engineered to infect professional APCs such as dendritic cells and macrophages. Dendritic cells are known to be orchestrators of a successful immune response especially that of a cell mediated response. It has been shown that *ex vivo* treatment of
30 dendritic cells with antigen or viral vectors containing such a target antigen, will induce efficacious immune responses when infused into syngeneic animals or humans (see Nestle FO, *et al*, Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells, Nat Med. 1998 Mar;4(3):328-32 and Kim CJ, *et al*. Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes *in vitro*.

J Immunother. 1997 Jul;20(4):276-86. The recombinant vectors can also infect tumour cells. Alternatively, the recombinant vectors are able to infect any cell in the mammal.

Other examples of vectors include *ex vivo* delivery systems, which include but are not limited to DNA transfection methods such as electroporation, DNA biolistics, lipid-mediated transfection and compacted DNA-mediated transfection.

The vector may be a plasmid DNA vector. As used herein, "plasmid" refers to discrete elements that are used to introduce heterologous DNA into cells for either expression or replication thereof. Selection and use of such vehicles are well within the skill of the artisan.

Pulsed cells

The present invention also provides cells pulsed with peptides of the first aspect of the invention.

Preferably the cells to be pulsed are capable of expressing MHC class I or class II.

MHC class I molecules can be expressed on nearly all cell types, but expression of MHC class II molecules is limited to so-called "professional" antigen presenting cells (APCs); B cells, dendritic cells and macrophages. However, expression of MHC class II can be induced on other cell types by treating with IFN γ .

Expression of MHC class I or MHC class II molecules can also be achieved by genetic engineering (i.e. provision of a gene encoding the relevant MHC molecule to the cell to be pulsed). This approach has the advantage that an appropriate MHC haplotype(s) can be chosen which bind specifically to the peptide(s).

Preferably the cell to be pulsed is an antigen presenting cell, i.e. a cell which, in a normal immune response, is capable of processing an antigen and presenting it at the cell surface in conjunction with an MHC molecule. Antigen presenting cells include B cells, macrophages and dendritic cells. In an especially preferred embodiment, the cell is a dendritic cell.

Preferably the cell is capable of expressing an MHC molecule which binds a peptide according to the first aspect of the invention in its peptide binding groove. For example, the cell may express one of the following HLA restriction elements: B8, Cw7 or A2 (for MHC class I).

5

Peptide pulsing protocols are known in the art (see for example Redchenko and Rickinson (1999) J. Virol. 334-342; Nestle et al (1998) Nat. Med. 4 328-332; Tjandrawan et al (1998) J. Immunotherapy 21 149-157). For example, in a standard protocol for loading dendritic cells with peptides, cells are incubated with peptide at 50 µg/ml with 3 µg/ml β-2 microglobulin

10

for two hours in serum free medium. The unbound peptide is then washed off.

The pulsed cell of the present invention may be used as a vaccine, for example to stimulate a prophylactic or therapeutic anti-5T4 immune response.

15

The present invention therefore also provides a method for treating and/or preventing a disease which comprises the step of administering a peptide-pulsed cell to a subject in need of same.

Vaccine/Pharmaceutical composition

20

The present invention also provides a vaccine/pharmaceutical composition comprising a peptide epitope, a polypeptide string,, a nucleic acid sequence, a vector system and/or a cell according to previous aspects of the invention.

25

The vaccine/pharmaceutical composition may be for prophylactic or therapeutic use.

The vaccine may be prepared as an injectable, either as liquid solution or suspension; solid form suitable for solution in, or suspension in, liquid prior to injection may also be prepared. The preparation may also be emulsified, or the protein encapsulated in liposomes. The active immunogenic ingredients are often mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like and combinations thereof.

30

In addition, if desired, the vaccine may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and/or adjuvants which enhance the effectiveness of the vaccine. Examples of adjuvants which may be effective include but are not limited to: aluminium hydroxide, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-
5 MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine (CGP 11637, referred to as nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylaminc (CGP 19835A, referred to as MTP-PE), and RIBI, which contains three components extracted from bacteria, monophosphoryl lipid A, trehalose dimycolate and cell wall skeleton (MPL+TDM+CWS) in a 2% squalene/Tween 80 emulsion.

10 Further examples of adjuvants and other agents include aluminium hydroxide, aluminium phosphate, aluminium potassium sulphate (alum), beryllium sulphate, silica, kaolin, carbon, water-in-oil emulsions, oil-in-water emulsions, muramyl dipeptide, bacterial endotoxin, lipid X, *Corynebacterium parvum* (*Propionobacterium acnes*), *Bordetella pertussis*,
15 polyribonucleotides, sodium alginate, lanolin, lysolecithin, vitamin A, saponin, liposomes, levamisole, DEAE-dextran, blocked copolymers or other synthetic adjuvants. Such adjuvants are available commercially from various sources, for example, Merck Adjuvant 65 (Merck and Company, Inc., Rahway, N.J.) or Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, Michigan).

20 Typically, adjuvants such as Amphigen (oil-in-water), Alhydrogel (aluminium hydroxide), or a mixture of Amphigen and Alhydrogel are used. Only aluminium hydroxide is approved for human use.

25 The proportion of immunogen and adjuvant can be varied over a broad range so long as both are present in effective amounts. For example, aluminium hydroxide can be present in an amount of about 0.5% of the vaccine mixture (Al_2O_3 basis). Conveniently, the vaccines are formulated to contain a final concentration of immunogen in the range of from 0.2 to 200 $\mu\text{g/ml}$, preferably 5 to 50 $\mu\text{g/ml}$, most preferably 15 $\mu\text{g/ml}$.

30 After formulation, the vaccine may be incorporated into a sterile container which is then sealed and stored at a low temperature, for example 4°C , or it may be freeze-dried. Lyophilisation permits long-term storage in a stabilised form.

The vaccine may be administered in a convenient manner such as by the oral, intravenous (where water soluble), intramuscular, subcutaneous, intranasal, intradermal or suppository routes or implanting (e.g. using slow release molecules).

- 5 The vaccines are conventionally administered parenterally, by injection, for example, either subcutaneously or intramuscularly. Additional formulations which are suitable for other modes of administration include suppositories and, in some cases, oral formulations. For suppositories, traditional binders and carriers may include, for example, polyalkylene glycols or triglycerides; such suppositories may be formed from mixtures containing the active
10 ingredient in the range of 0.5% to 10%, preferably 1% to 2%. Oral formulations include such normally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, and the like. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and contain 10% to 95% of active ingredient, preferably 25%
15 to 70%. Where the vaccine composition is lyophilised, the lyophilised material may be reconstituted prior to administration, e.g. as a suspension. Reconstitution is preferably effected in buffer.

- Capsules, tablets and pills for oral administration to a patient may be provided with an enteric
20 coating comprising, for example, Eudragit "S", Eudragit "L", cellulose acetate, cellulose acetate phthalate or hydroxypropylmethyl cellulose.

- 5T4 peptides may be formulated into the vaccine as neutral or salt forms. Pharmaceutically acceptable salts include the acid addition salts (formed with free amino groups of the peptide)
25 and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids such as acetic, oxalic, tartaric and maleic. Salts formed with the free carboxyl groups may also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine and procaine.

30

Heterologous vaccination regimes

Regimes for administration of vaccines/pharmaceutical compositions according to the present invention may be determined by conventional efficacy testing. Especially preferred, however,

are regimes which include successive priming and boosting steps. It is observed that such regimes achieve superior breaking of immune tolerance and induction of T cell responses (see Schneider *et al.*, 1998 Nat Med 4:397-402).

- 5 Prime-boost regimes may be homologous (where the same composition is administered in subsequent doses) or heterologous (where the priming and boosting compositions are different). For example, the priming composition may be a non-viral vector (such as a plasmid) encoding a 5T4 antigen and the boosting composition may be a viral vector (such as a poxvirus vector) encoding a 5T4 antigen, wherein either or both of said "5T4 antigens" is an
10 epitope or polypeptide string of the present invention.

Diagnostic methods

- The present invention also provides an agent capable of binding specifically to a peptide
15 according to the present invention and/or a nucleic acid sequence which encodes such a peptide.

- An agent is considered to "bind specifically" to a peptide/nucleic acid sequence of the present invention if there is a greater than 10 fold difference, and preferably a 25, 50 or 100 fold
20 difference between the binding of the agent to a peptide/nucleic acid sequence of the present invention and another peptide/nucleic acid sequence.

- The agent may be any compound capable of binding specifically to a peptide and/or a nucleic acid sequence. The term "compound" refers to a chemical compound (naturally occurring or
25 synthesised), such as a biological macromolecule (e.g., nucleic acid, protein, non-peptide, or organic molecule), or an extract made from biological materials such as bacteria, plants, fungi, or animal (particularly mammalian) cells or tissues, or even an inorganic element or molecule.

- 30 Preferably the agent is identifiable by screening a library of candidate compounds. Libraries of compounds may be screened in multi-well plates (e.g., 96-well plates), with a different test compound in each well. In particular, the library of candidate compounds may be a combinatorial libraries. A variety of combinatorial libraries of random-sequence oligonucleotides, polypeptides, or synthetic oligomers have been proposed and number of

small-molecule libraries have also been developed. Combinatorial libraries of oligomers may be formed by a variety of solution-phase or solid-phase methods in which mixtures of different subunits are added stepwise to growing oligomers or parent compound, until a desired oligomer size is reached (typically hexapeptide or heptapeptide). A library of increasing complexity can be formed in this manner, for example, by pooling multiple choices of reagents with each additional subunit step. Alternatively, the library may be formed by solid-phase synthetic methods in which beads containing different-sequence oligomers that form the library are alternately mixed and separated, with one of a selected number of subunits being added to each group of separated beads at each step. Libraries, including combinatorial libraries are commercially available from pharmaceutical companies and speciality library suppliers.

Where the agent recognises a nucleic acid according to the present invention, the agent may comprise an antisense sequence.

Where the agent recognises a peptide according to the present invention, the agent may comprise an MHC molecule or part thereof which comprises the peptide binding groove. Alternatively the agent may comprise an anti-peptide antibody.

As used herein, "antibody" includes a whole immunoglobulin molecule or a part thereof or a bioisostere or a mimetic thereof or a derivative thereof or a combination thereof. Examples of a part thereof include: Fab, F(ab)'₂, and Fv. Examples of a bioisostere include single chain Fv (ScFv) fragments, chimeric antibodies, bifunctional antibodies.

The term "mimetic" relates to any chemical which may be a peptide, polypeptide, antibody or other organic chemical which has the same binding specificity as the antibody.

The term "derivative" as used herein in relation to antibodies includes chemical modification of an antibody. Illustrative of such modifications would be replacement of hydrogen by an alkyl, acyl, or amino group.

A whole immunoglobulin molecule is divided into two regions: binding (Fab) domains that interact with the antigen and effector (Fc) domains that signal the initiation of processes such as phagocytosis. Each antibody molecule consists of two classes of polypeptide chains, light

(L) chains and heavy (H) chains. A single antibody has two identical copies of the L chain and two of the H chain. The N-terminal domain from each chain forms the variable regions, which constitute the antigen-binding sites. The C-terminal domain is called the constant region. The variable domains of the H (V_H) and L (V_L) chains constitute an Fv unit and can
5 interact closely to form a single chain Fv (ScFv) unit. In most H chains, a hinge region is found. This hinge region is flexible and allows the Fab binding regions to move freely relative to the rest of the molecule. The hinge region is also the place on the molecule most susceptible to the action of protease which can split the antibody into the antigen binding site (Fab) and the effector (Fc) region.

10 The domain structure of the antibody molecule is favourable to protein engineering, facilitating the exchange between molecules of functional domains carrying antigen-binding activities (Fabs and Fvs) or effector functions (Fc). The structure of the antibody also makes it easy to produce antibodies with an antigen recognition capacity joined to molecules such as
15 toxins, lymphocytes or growth factors.

Chimeric antibody technology involves the transplantation of whole mouse antibody variable domains onto human antibody constant domains. Chimeric antibodies are less immunogenic than mouse antibodies but they retain their antibody specificity and show reduced HAMA
20 responses.

In chimeric antibodies, the variable region remains completely murine. However, the structure of the antibody makes it possible to produce variable regions of comparable specificity which are predominantly human in origin. The antigen-combining site of an
25 antibody is formed from the six complementarity-determining regions (CDRs) of the variable portion of the heavy and light chains. Each antibody domain consists of seven antiparallel β -sheets forming a β -barrel with loops connecting the β -strands. Among the loops are the CDR regions. It is feasible to move the CDRs and their associated specificity from one scaffolding β -barrel to another. This is called CDR-grafting. CDR-grafted antibodies appear in early
30 clinical studies not to be as strongly immunogenic as either mouse or chimaeric antibodies. Moreover, mutations may be made outside the CDR in order to increase the binding activity thereof, as in so-called humanised antibodies.

Fab, Fv, and single chain Fv (ScFv) fragments with VH and VL joined by a polypeptide linker exhibit specificities and affinities for antigen similar to the original monoclonal antibodies. The ScFv fusion proteins can be produced with a non-antibody molecule attached to either the amino or carboxy terminus. In these molecules, the Fv can be used for specific
5 targeting of the attached molecule to a cell expressing the appropriate antigen. Bifunctional antibodies can also be created by engineering two different binding specificities into a single antibody chain. Bifunctional Fab, Fv and ScFv antibodies may comprise engineered domains such as CDR grafted or humanised domains.

10 Procedures for identifying, characterising, cloning and engineering polyclonal and monoclonal antibodies and their derivatives are well established, for example using hybridomas derived from mice or transgenic mice, phage-display libraries or scFv libraries. Genes encoding immunoglobulins or immunoglobulin-like molecules can be expressed in a variety of heterologous expression systems. Large glycosylated proteins including
15 immunoglobulins are efficiently secreted and assembled from eukaryotic cells, particularly mammalian cells. Small, non-glycosylated fragments such as Fab, Fv, or scFv fragments can be produced in functional form in mammalian cells or bacterial cells.

The agent may recognise the peptide/nucleic acid of the present invention alone, or in
20 conjunction with another compound. For example, the agent may be capable of binding specifically to the peptide when presented by an MHC molecule. In this case, the agent of the present invention may comprise a T cell receptor molecule or part thereof.

The T cell receptor may be associated with another molecule such as CD4 (for MHC class II
25 epitopes) or CD8 (for MHC class I epitopes). Alternatively, or in addition, the receptor may be associated with CD3.

If the agent occurs naturally in the human body, then preferably the agent of the present invention is in a substantially isolated form.

30

The present invention also provides a method which comprises the step of detecting the presence of a peptide, nucleic acid or agent of the present invention in a subject.

In a preferred embodiment, the method is used to detect the presence of T cells capable of

specifically recognising a peptide epitope according to the present invention in conjunction with an MHC molecule.

5 The diagnostic method may, for example, be for diagnosing or monitoring the progression of a disease or for monitoring the progression of an immune response in a subject.

As mentioned above, as an immune response progresses, the dominance of particular epitopes may change, and sub-dominant epitopes can predominate. Thus by detecting the presence of a particular epitope, or a TCR/T cell capable of recognising such an epitope, information can
10 be gained about the progression of the immune response.

The method may be carried out *in vivo*, or more preferably on an *ex vivo* sample.

Thus the present invention also provides a diagnostic method which comprises the following
15 steps:

- (i) isolating a sample from a subject;
- (ii) detecting in the sample *ex vivo* the presence of T cells capable of specifically recognising a peptide epitope according to the present invention in conjunction with an MHC molecule.

20

In a preferred embodiment, the method is for diagnosing or monitoring the progression of a cancerous disease.

The nature of the method will depend on whether a peptide, nucleic acid or agent of the
25 present invention is being detected (and if it is an agent, on the nature of that agent).

In order to detect a peptide of the present invention, an agent of the present invention (such as an antibody or an MHC molecule) may be used. Methods of screening with antibodies (such as ELISAs, immunoblotting, western blotting, competitive assays, two site capture assays) are
30 well known in the art.

In order to detect peptides or specific T cells, an antigen presentation assay may be used. When a T cell successfully recognises an MHC:peptide complex, it is stimulated. This stimulation can be monitored by proliferation of the T cells (for example by incorporation of

³H) and/or by production of cytokines by the T cells (for example by an ELISPOT assay). Thus it is possible to detect the presence of a specific peptide by using appropriate APCs and T cells lines, and to detect the presence of a specific T cell by using appropriate APCs and peptide/antigen.

5

The presence of a particular cell surface molecule (such as a TCR or MHC molecule) can also be investigated using fluorescence activated cell scanning (FACS).

Where the method is to detect the presence of a nucleic acid, numerous methods are known in the art such as PCR, southern blotting (for DNA) and northern blotting (for RNA).

10

T cells

The present invention also relates to a T cell, such as a T cell clone, or line, which is capable of specifically recognising a peptide epitope according to the present invention in conjunction with an MHC molecule. Several methods for generating T cell lines and clones are known in the art. One method for generating T cell lines is as follows:

15

Mice are primed with antigen (usually subcutaneously in the rear footpad), and the draining lymph nodes (in this case the popliteal and inguinal) are removed 1 week later and set up in co-culture with the antigen and with syngeneic feeder cells i.e. cells from mice of the same inbred line (e.g. normal thymocytes or splenocytes). After 4 days the lymphoblasts are isolated and induced to proliferate with IL-2. When the population of cells has expanded sufficiently, they are checked for antigen and MHC specificity in a lymphocyte transformation test, and are maintained by alternate cycles of culture on antigen-treated feeder cells and culture in IL-2-containing medium.

20

25

The definitive T-cell lineage marker is the T-cell receptor (TCR). There are presently two defined types of TCR, both of which are heterodimers of two disulphide-linked polypeptides. One type consist of α and β chains, the other type consists of γ and δ chains. Approximately 90-95 % of blood T cells express α/β TCR, the other 5-10% expressing γ/δ TCR.

30

T cells can be divided into two distinct populations: a subset which carries the CD4 marker and mainly "helps" or "induces" immune responses (T_H) and a subset which carries the CD8

marker and is predominantly cytotoxic (T_C). $CD4^+$ T cells recognise peptides in association with MHC class II molecules, whereas $CD8^+$ T cells recognise peptides in association with Class I molecules, so the presence of CD4 or CD8 restricts the types of cell with which the T cell can interact.

5

The CD4 set has been functionally sub-divided into two further subsets:

- (i) T cells that positively influence the response of T cells and B cells (the helper T cell function) are $CD29^+$. Practically all the cells in this population also express a low molecular weight isoform of the CD45 leucocyte common antigen, designated
10 $CD45RO$.
- (ii) Cells that induce the suppressor/cytotoxic functions of $CD8^+$ cells (the suppressor/inducer function) express a different form of the CD45 molecule,
20 $CD45RA$.

Functional diversity has also been demonstrated by functional analysis of T_H clones for
15 cytokine secretion patterns. The T_H1 subset of $CD4^+$ T cells secrete IL-2 and IFN- γ , whereas the T_H2 subset produces IL-4, IL-5, IL-6 and IL-10. T_H1 cells mediate several functions associated with cytotoxicity and local inflammatory reactions. Consequently these cells are important for combating intracellular pathogens, including viruses, bacteria and parasites. T_H2 cells are more effective at stimulating B cells to proliferate and produce antibodies, and
20 therefore in normal immune responses function to protect against free-living organisms.

Expression of all of the markers described above can readily be detected using specific antibodies, so the type of T cell can be selected/determined using FACS. Expression of particular cytokines can also be detected by methods known in the art, such as ELISPOT
25 assay.

Prophylactic/Therapeutic methods

The present invention also provides the use of a vaccine according to the present invention in
30 the manufacture of a medicament for use in the prevention and/or treatment of a disease.

There is also provided a method for treating and/or preventing a disease in a subject which comprises the step of administering an effective amount of a vaccine according to the present invention.

Administration of the vaccine may elicit an immune response in the subject. In a preferred embodiment, administration of the vaccine breaks immune tolerance to 5T4 in the subject.

- 5 Where the peptide is a class I epitope, the immune response elicited may involve the activation of 5T4 specific cytotoxic T-lymphocytes. Where the peptide is a class II epitope, the immune response elicited may involve the activation of T_H1 and/or T_H2 cells.

- Advantageously, the response is an anti-tumour immunotherapeutic response which is
10 effective to inhibit, arrest or reverse the development of a tumour in a subject.

Combination therapies

- The invention further relates to the use of 5T4 targeting molecules, such as anti-5T4
15 antibodies, for example anti-5T4 scFvs. These antibodies may be used to (i) to target natural or exogenous 5T4 *in situ* and/or (ii) deliver immune enhancer molecules, such as B7.1, to natural or exogenous 5T4 *in situ* (Carroll *et al.* (1998) J Natl Cancer Inst 90(24):1881-7). This potentiates the immunogenicity of 5T4 in the subject.

- 20 The present invention thus also relates to the sequential use of a vaccine according to the present invention and anti-5T4 antibodies, for example anti-5T4 scFvs. The anti-5T4 scFvs antibodies may be administered as naked DNA encoding the antibodies (for example, in a plasmid comprising the encoding DNA together with a short promoter region to control its production), in an expression vector (which may be viral or non-viral) comprising the
25 encoding sequence or in a protein form. Thus, the invention provides a vector encoding a 5T4 peptide antigen and an agent capable of binding 5T4 which is optionally fused with an immunostimulatory molecule, for separate, such as sequential use, in the treatment of tumours.

- 30 In a further embodiment, the invention encompasses a combination therapy including enzyme/prodrug therapy and immunotherapy with 5T4. For example, the enzyme/prodrug therapy may comprise intratumoural or systemic delivery of P450, delivered optionally using an retroviral or lentiviral vector, and cyclophosphamide (CPA) followed by systemic immunotherapeutic induction with 5T4.

Thus, the invention further relates to a vector encoding 5T4 peptide antigen and a prodrug/enzyme combination, for separate, simultaneous separate or combined use in the treatment of tumours.

5

Diseases

5T4 is a tumour associated antigen. Presence of 5T4 on cancer cells is associated with metastasis and has been shown to be an independent indicator of prognosis in a number of different cancers.

10

In a preferred embodiment, the disease (which is preventable/treatable using a vaccine according to the present invention) is a cancer. In particular the disease may be a carcinoma of, for example, the breast, lung, stomach, pancreas, endometrium, cervix, colorectal, renal or prostate.

15

WO89/07947 describes an immunohistochemical screen of neoplastic tissues using an anti-5T4 monoclonal antibody (see Tables II and VI). Preferably, the disease is a cancer which can be shown to be 5T4 positive by diagnostic testing (such as with an anti-5T4 antibody), for example: an invasive carcinoma of the Ampulla of Vater, breast, colon, endometrium, pancreas, or stomach; a squamous carcinoma of the bladder, cervix, lung or oesophagus; a tubulovillous adenoma of the colon; a malignant mixed Mullerian tumour of the endometrium; a clear cell carcinoma of the kidney; a lung cancer (large cell undifferentiated, giant cell carcinoma, broncho-alveolar carcinoma, metastatic leiomyosarcoma); an ovarian cancer (a Brenner tumour, cystadenocarcinoma, solid teratoma); a cancer of the testis (seminoma, mature cystic teratoma); a soft tissue fibrosarcoma; a teratoma (anaplastic germ cell tumours); or a trophoblast cancer (choriocarcinoma (e.g. in uterus, lung or brain), tumour of placental site, hydatidiform mole).

25

Tetramers

30

The present invention also provides 5T4 peptide epitope associated with (eg. folded with) tetramers and uses thereof.

Tetramers are fluorescent reagents that allow for the direct visualisation of antigen-specific T-cells (Altman et al. (1996) Science 271, 94-96). They consist of individual peptides epitopes refolded with HLA class I protein and bind to T cells that are specific for that particular epitope. They allow for the direct quantification of antigen specific lymphocytes and have
5 been applied widely in human and murine immunology.

The tetramers may be prepared using the methods described by Altman et al. (1996) Science 271, 94-96. Briefly, tetramers may be prepared by adding biotinylated protein to streptavidin PE at a ratio of 4:1. Tetramer bound cells may be selected using magnetic activated cell
10 sorting (MACS). MACS has been described in Radbruch *et al.* (1994) Methods in Cell Biology 42, 387-403.

Advantageously, the use of tetramers allows for the tracking of a 5T4-specific immune response before, during and after vaccination; to purify autologous CD4+ T cells from
15 individual patients and expand/manipulate them *ex vivo* for possible re-infusion; as a diagnostic indicator, for example, in subjects prone to colorectal and other 5T4-positive cancers. Accordingly, the present invention also relates to the use of a 5T4 peptide epitope tetramer for monitoring a 5T4-specific immune response before, during or after vaccination. The present invention further relates to the use of a 5T4 peptide epitope tetramer for the
20 purification of autologous CD4+ T cells from individual patients. The present invention still further relates to the use of a 5T4 peptide epitope tetramer as a diagnostic indicator in subjects prone to 5T4-positive cancers – such as colorectal cancers.

The invention is further described, for the purposes of illustration only, in the following
25 examples in which reference is made to the following Figures.

Figure 1 shows an ELISpot assay which reveals the presence of T cells specific for one of 5T4 peptide pools in the PBMCs from healthy donor *ex vivo*.

- A. whole PBMCs
- 30 B. CD4 depleted PBMCs

Figure 2 shows an ELISpot screen of the peptides constituting pool 8 to investigate which one(s) is responsible for inducing IFN gamma secretion.

Figure 3 shows a ^{51}Cr -release assay showing that expanded 5T4-specific OB8 T cells recognise allogeneic CMC LCL target cells expressing 5T4 endogenously from MVA vector.

Figure 4 shows that individual OB8 T cell clones isolated by limiting dilution are also 5T4-specific when tested by ^{51}Cr -release assay.

Figure 5 shows IFN gamma production by OB8 T cell clones.

Figure 6 shows a screen of p77 derivatives to identify the minimal epitope of P77.

Figure 7 shows an OB8 CTL assay

Figure 8 shows an OB8 ELISpot assay

Figure 9 shows FACS analysis of 5T4 expression in DCs infected with recombinant Adenovirus encoding 5T4.

Figure 10 shows an ELISpot assay of T cell microculture using 5T4 peptide pools.

Figure 11 shows the amino acid sequences 14.2 and 14.3 peptides

Figure 12 shows an ELISpot assay of T cell microculture using individual peptides from pool 14.

Figure 13 shows blocking of target cell recognition with anti-HLA A2 antibodies in ^{51}Cr -release assay.

Figure 14 shows the amino acid sequence of shorter versions of the 14.3 and 14.2 peptides.

Figure 15 shows the ^{51}Cr -release assay with 5T4 specific T cell microculture against autologous LCL loaded with the peptides

EXAMPLES

5T4-specific immune response in healthy donors.

5 H5T4 is a surface glycoprotein which is expressed on trophoblasts during gestation period but it is not present on normal adult tissues, with only weak expression on some specialised epithelia. By contrast, it is expressed by many human carcinomas. Its function is unknown but there is significant correlation between 5T4 expression and poor clinical prognosis. There is some evidence that primary 5T4-negative tumours give rise to 5T4-positive metastases.

10 Due to the fact that 5T4 is a self-protein, one may suspect that T cells specific for this protein should be eliminated during thymic development. However, there is evidence that low frequency low affinity 5T4-specific T cells exist in some people. Extensive studies on melanoma have shown that T cells reactive against self tissue-specific gene products can be detected in both melanoma patients and healthy individuals.

15 On the basis that the same may be true for the 5T4 antigen, the present inventors have undertaken random screening of healthy donors for the presence of 5T4-specific T cells *ex vivo*.

Example 1 - Screening of a 5T4 peptide library

20 A 5T4 peptide library spanning the entire 5T4 protein and consisting of 10-mer peptides overlapping by 8 amino acids. was used in an ELISpot assay.

25 ELISpot assay was performed as described elsewhere (Czerkinsky et al (1988) in "Theoretical and Technical Aspects of ELISA and Other Solid Phase Immunoassays (D.M.Kemeny and S.J. Challacombe, eds.) pp217-239 John Wiley & Sons, New York). Briefly, PBMCs were separated by Histopaque-1077 and plated out at concentration of 5×10^5 cells per well of PVDF 96-well plate covered with interferon-capturing antibody. Pools of ten peptides were added to each well at final concentration of 20 ug/ml. Wells with DMSO and PHA served as negative and positive controls respectively. Also Influenza peptide was included as positive control. After O/N incubation a plate was washed with PBS-Tween and second-step antibody 30 were added. The number of spots was counted by dissection microscope.

Out of 20 healthy blood donors tested against 5T4 peptide library one donor, OB8, had a positive response to the peptide pool #8. PBMCs exposed to 5T4 peptide pool 8 produced 5 spots per 5×10^5 cells compared to no spots in response to any other peptide pools (Figure 1A). Response to a Flu peptide was used as a positive control. CD4 depletion of PBMCs prior to
 5 ELISpot assay significantly amplified the response (37 spots per 5×10^5 PBMCs) which led to the conclusion that IFN-gamma production was mediated by CD8+ T cells. (Fig.1B).

Peptide pool #8 was pulled apart and each individual peptide was tested by ELISpot in a similar way, using whole PBMC and CD4-depleted PBMC from donor OB8, which allowed
 10 us to identify a single epitope-peptide within 5T4 which was responsible for inducing secretion of IFN γ -p77, PLADLSFAF (Fig.2).

Example 2 - Testing the 5T4 specificity of OB8 T cells

15 To further characterize identified the epitope, an EBV-transformed B-cell line was established from this donor. The HLA class I type of donor OB8 was identified as HLA A **1,2** B **8,44** C **5,7**.

Peptide 77-specific T cells were expanded in vitro by co-culturing PBMC from OB8 with
 20 autologous DC pulsed with p77. After 3 weekly stimulations with autologous DC+p77 resulting polyclonal T cell line was tested for the presence of specific reactivity by CTL assay (Fig.3). OB8 T cells recognized HLA-matched CMC LCL expressing the whole 5T4 antigen from an MVA vector over the background killing of MVA-LacZ-infected targets.

25 By cloning by limiting dilution T cell clones were generated from polyclonal T cell line using p77-pulsed autologous LCL. The clones were expanded to growth in 2ml wells and then tested for specific reactivity by ^{51}Cr -release assay. Autologous LCL, untreated, pulsed with p77, infected with TroVax and control vector were used as targets. About 35% of clones tested were specific for the whole antigen endogenously expressed in LCL from MVA vector.
 30 Representative results of a CTL assay are shown in Fig.4.

Both cytolytic and non-cytolytic clones were tested for IFN-gamma production by ELISpot. Some of the non-cytolytic clones produced IFN-gamma in response to stimulation with LCL

loaded with p77 and infected with TroVax. The level of IFN production is expressed in relative units compared to background (Fig.5).

Example 3 - Identification of the HLA restriction element for the p77 epitope

5

The next step was to identify an HLA restriction element of an epitope-peptide. LCLs which matched at one or two HLA alleles loaded with p77 were used as APCs in ELISpot assay. This is a panel of LCLs used as APCs:

- 10 CMC – HLA **A2**,11 **B8,44** **C5**,7
 CD – HLA **A1** B7,57, **C6**,7
 IM17 – HLA **A1,2** B13,**44** **C5**, 6
 IM 108 – HLA A3,11 **B8**,35 **C4**,7
 IM 119 – HLA **A2**,68 B15,40 C3

15

LCLs IM17 and IM119 loaded with p77 did not induce IFN-gamma production by OB8 CTLs which rules out HLA A1, A2, B44 and C5 alleles as restriction elements for the epitope. The strength of the response induced by other LCLs can be characterized as following:

- 20 Auto LCL>CMC LCL>IM108 LCL>CD LCL

LCL + p77	No. of spots per 1000 cells
Auto	>100
CMC	15.3
IM 108	12
CD	3.7

25

The fact that p77 induced a response from strong to medium when autologous and two B8-matched LCLs were used as APCs leads to a conclusion the epitope is likely to be presented through B8 allele. However, there is a possibility that this peptide may also be presented by Cw7 allele also, because of the fact that CD LCL matched at Cw7 induce weak response as well.

30

Example 4 - Identification of the minimal epitope

In order to minimise HLA B8-restricted 5T4 epitope the peptides were synthesized which presented shorter or longer version of original p77. A number of clones were tested by CTL assay against LCL loaded with individual peptide in a ⁵¹Cr-release assay. One of the clones tested recognised a 9-mer peptide but there was no killing of LCL loaded with any other peptide. This led to the conclusion that c5 corresponds to the minimal epitope (Fig.6).

The blood sample from the same donor was obtained 1 year later and polyclonal T cell line was generated de novo in a similar way using a defined minimal epitope peptide c5 to load DCs. After 4 weekly stimulations the growing cell population was tested by Cr-release and ELISpot assays. As targets for Cr-release assay and APCs for ELISpot assay the following LCLs were used: autologous LCL, IM 17 LCL (HLA A1,2 B13,44 C5, 6) and GS LCL (HLA A2,29 B7,44, C7,16). CTLs strongly recognized autologous LCL loaded with c5 peptide reaching the level of killing of 70%. There was no recognition of IM17 targets pulsed with the peptide as was observed in a previous experiment. However, GS LCL loaded with c5 peptide were killed by OB8 CTLs but the levels of killing were lower (Fig.7). The results of cytotoxicity assay correlated with ELISpot data (Fig.8).

Taken together, this leads to the conclusions that

- either defined 5T4 epitope is presented by HLA B8 allele and cross-presented by Cw7 allele,
- or it's presented by Cw7 allele only and in this case weaker recognition of Cw7-matched allogeneic LCL is due to the fact they are of different Cw7 subtype.

The Cw7 allele has not been characterized as extensively as others in regard to its primary anchor motifs. However, alanine in position 3 has been mentioned as one of those motifs (Marsh S, Parham P, Barber L The HLA Facts Book, Academic Press, 2000) which makes the Cw7 allele the most likely restriction element for the epitope.

This issue can be clarified by using cell lines expressing singular HLA allele, B8 or Cw7, as targets in Cr-release assay and/or APCs in ELISpot assay.

Example 5 - stimulation of CD8+ cells in vitro by DCs expressing 5T4

The present inventors have also demonstrated that dendritic cells (DCs), being professional APCs, can prime 5T4-specific IR in healthy donors in vitro. To this end, PBMCs from a HLA A2-positive healthy donor (HD123) were enriched for CD8⁺ T cells by negative selections. Autologous DCs, grown in the bags according to IDM technique, were infected with TroVax and added to respective CD8⁺ T cells to establish microcultures. After three-five rounds of weekly re-stimulations with TroVax-infected DCs resulting T cell microcultures were tested for the presence of 5T4-specific CTLs by Cr-release assay against autologous DC infected with recombinant adenovirus expressing 5T4 as target cells. Expression of 5T4 from adenoviral vector in target cells was tested prior to conducting a CTL assay (Fig.9). FACS ananlysis using an anti-5T4 antibody showed that 75% of DCs (infected with recombinant adenovirus encoding 5T4) expressed 5T4.

After 3 IVS some of the T cell microcultures showed weak (about 12-15%) 5T4-specific killing of autologous target cells. Those T cells were tested for IFN gamma production by ELISpot. Autologous DCs expressing whole protein from adcnoviral vector and loaded with 5T4 peptide pools as described above were used as stimulator cells. Some T cell microcultures were 5T4 positive, producing 130 spots per 103 cells in response to DC infected with Ad.5T4. These T cells were also positive to peptide pool 14 of 5T4 (92 spots per 103 cells). This the single peptide pool #14 was identified as being the one which induced IFN gamma secretion by T cells (Fig.10).

An ELISpot assay was repeated after 4 IVS with the similar result. The individual 10-mer peptides constituting pool 14 were included into this assay which identified two adjacent peptides as inducing positive response – p14.2 and p14.3 (Fig.11), although the response induced by p14.3 was significantly stronger (Fig.12). Two more T cell microcultures were tested by ELISpot in a similar way and one out of two microcultures appeared to be 5T4-specific with the same p14.3 inducing IFN gamma production. Taken together these data lead to suggestion that p14.3 is a naturally processed CD8 T cell cpitope within 5T4 antigen.

To test the possibility of HLA A2 allele being restricting element for identified epitope the present inventors performed Cr-release assay using, as target cells, autologous DCs pretreated with anti HLA A2 antibody prior to peptide sensitization with p14.3. In more detail, three T cell microcultures C8, C11 and E5 were tested against peptides 14.2 and 14.3-pulsed targets by 51Cr-release assay. Peptide 14.3 was recognised by all three T cell microcultures and only

C11 T cells killed p14.2-loaded targets at low level. When Dcs were pretreated with anti-HLA A2 Abs prior to pulsing with p14.3, their recognition by T cells was abrogated. These results demonstrate that p14.3 is indeed presented by HLA A2 allele.(Fig.13).

- 5 Blood sample from the same donor was obtained 6 months later. To confirm that the 5T4-specific response is a primary response, CD8+ T cells were separated into naïve and memory T cells on the basis of CD45RA expression. T cells microcultures were set up from total CD8+ T cells, CD8+CD45RA+ and CD8+CD45RA- T cells. After 5 rounds of weekly stimulation with TroVax-infected DCs T cell microcultures were tested by the 51Cr-release assay as described above. None of the T cell microcultures generated from CD45RA- cells were
10 cytotoxic, whereas both total CD8+ T cells and CD45RA+ CD8+ T cells produced 5T4-specific populations which proves that 5T4-specific immune response was primed in vitro. These T cell cultures were used to identify a minimal epitope within a 10-mer peptide as had been done for donor OB8. 51Cr-release assay was performed using autologous LCL loaded
15 with 14.3 and 14.2 peptides, including in the assay three other peptides representing shorter versions of 14.3 and 14.2 (Fig. 14). According to the binding prediction algorithms 9-mer peptide #3 is the strongest candidate for an HLA A2-restricted minimal epitope, having Leucine in position 2 and Valine in position 9 as primary anchor residues. However, in contrast to our expectations, original peptide 14.3 induced the strongest response (Fig. 15).
20 These data were corroborated by ELISpot assay (data not shown). Based on these data, we conclude that a10-mer peptide 14.3 is a natural A2-restricted epitope within 5T4 antigen. To support this, HLA A2 tetramer complexed with 14.3 peptide has been made despite the fact that generally Glutamic acid in position 2 has a negative effect on peptide folding within MHC groove and the success of making such a tetramer is usually poor.

- 25 In the course of monitoring an immune response in colorectal cancer patients by ex vivo ELISpot assay we have detected a response to pool 8 containing the earlier described peptide 77 in a patient whose HLA type included Cw7 allele. Two other patients (HLA type unknown) have demonstrated a response to peptide pool 10.

- 30 A patient with HLA type A2,11 B7,27, Cw2,7 has responded to pool 11. Pool 11 contains a number of peptides that according to binding prediction algorithms are among the strongest binders to HLA A2 and B27 alleles. For instance, peptide 11.2 has got a top score among 5T4 10-mer peptides binding to HLA A2 allele; peptide 11.4 is the 7th from the top among A2-

binders. Peptide 11.7 has got a top score among 5T4 10-mer peptides binding to HLA B27 allele; peptide 11.3 is the 2nd and 11.4 is the 5th from the top among B27-binders. All publications mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described methods and system of the invention

5 will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described mode for carrying out the invention which are obvious to those skilled in the

10 molecular biology or related fields are intended to be within the scope of the following claims.

Each document, reference, patent application or patent cited in this text is expressly incorporated herein in their entirety by reference, which means that it should be read and considered by the reader as part of this text. That the document, reference, patent

15 application, or patent cited in this text is not repeated in this text is merely for reasons of conciseness.

Reference to cited material or information contained in the text should not be understood as a concession that the material or information was part of the common general

20 knowledge or was known in Australia or any other country.

Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer

25 or group of integers.

CLAIMS

1. An isolated MHC Class I peptide epitope of 5T4, which comprises one of the following:
 - (i) the amino acid sequence shown as SEQ ID No. 2;
 - (ii) the minimal epitope from the amino acid sequence shown as SEQ ID No. 3;
 - (iii) the minimal epitope from the amino acid sequence shown as SEQ ID No. 4.
 - (iv) the minimal epitope from the amino acid sequence shown as SEQ ID No. 5.
 - (v) the minimal epitope from the amino acid sequence shown as SEQ ID No. 6.
 - (vi) the minimal epitope from the amino acid sequence shown as SEQ ID No. 7.
2. An isolated polypeptide string comprising a plurality of antigenic epitopes linked together, the epitope including:
 - (i) at least one peptide epitope according to claim 1; and
 - (ii) at least one epitope from another antigen.
3. A peptide epitope according to claim 1 or a polypeptide string according to claim 2 in association with a cell penetrator.
4. A peptide epitope according to claim 1 or a polypeptide string according to claim 2 associated with a tetramer.
5. An isolated nucleic acid sequence capable of encoding a peptide epitope according to any one of claims 1, 3 or 4 or a polypeptide string according to any one of claims 2, 3 or 4.
6. A vector system capable of delivering a nucleic acid sequence according to claim 5 to a cell.
7. A cell pulsed with a peptide epitope according to any one of claims 1, 2, 4 or 5 or a polypeptide string according to any one of claims 3 or 4 or 5, a nucleic acid sequence according to claim 5, or a vector system according to claim 6.
8. An antigen presenting cell according to claim 7.
9. A vaccine comprising a peptide epitope according to claims 1, 2, 4 or 5 or a polypeptide string according to claims 3, 4 or 5, a nucleic acid sequence according to claim 5, a vector system according to claim 6, and/or a cell according to claim 7 or 8.

10. The use of a vaccine according to claim 9 in the manufacture of a medicament for use in the prevention and/or treatment of a disease.
11. The use according to claim 10, wherein the disease is cancer.
12. A diagnostic method which comprises the following steps: (i) isolating a sample
5 from a subject;
(ii) detecting in the sample *ex vivo* the presence of a peptide epitope according to claim 1 or a nucleic acid according to claim 5 in a subject.
13. A diagnostic method which comprises the following steps: (i) isolating a sample from a subject;
10 (ii) using a peptide epitope according to claims 1, 3 or 4 in an antigen presentation assay to detect T cells capable of specifically recognising the peptide epitope in conjunction with an MHC molecule.
14. A method according to claims 12 or 13, for diagnosing or monitoring the progression of a cancerous disease.
15. A T cell line or clone capable of specifically recognising a peptide epitope according to claim 1 or 2 in conjunction with an MHC class I molecule.
16. The use of a T cell line or clone according to claim 15 in the manufacture of a medicament for treating and/or preventing a disease.
17. An isolated MHC Class I peptide according to claim 1 substantially as herein
20 before described with reference to the Examples.
18. A method according to claim 12 or 13 substantially as herein before described with reference to the Examples.

1 / 10




FIG. 1

SUBSTITUTE SHEET (RULE 26)

2 / 10




FIG. 2




FIG. 3

SUBSTITUTE SHEET (RULE 26)




FIG. 4

SUBSTITUTE SHEET (RULE 26)

Stimulation Clone No.		IFN-γ production by OB8 T cell clones				EXPERIMENT		
		CONTROLS (background)				T cells + LCL		
		T cells	LCL	T cells + LCL	T cells + MVA-LacZ	TroVax	p77	
Cytolytic	47	-	-	+++	+++	++++	+++	+++
	77	-	-	++	++	+++	++	++
Non-Cytolytic	30	-	-	++	++	+++	+++	+++
	32	-	-	-	-	+	-	-
	37	-	-	-	-	+	+	+
	43	-	-	++	++	+++	+++	+++
	44	-	-	++	++	++	++	++

FIG. 5

	Target cells	Auto LCL	Auto LCL+	Auto LCL+	Auto LCL+	Auto LCL+	Auto LCL+	Auto LCL+	Auto LCL+	Auto LCL+	Auto LCL+	Auto LCL+
			p77	c1	c2	c3	c4	c5	c6	c7	c8	
	Spont / Max	81 / 1209	95 / 1127	76 / 1089	86 / 1152	97 / 1182	94 / 1194	68 / 1077	80 / 1063	79 / 1145	86 / 942	
Clone No.												
14		73	69	76	70	74	73	78	72	73	76	
15		10	9	10	6	12	8	27	12	10	10	
21		9	8	9	7	10	6	8	11	8	10	
32		22	21	21	22	22	21	23	22	22	23	
95		44	41	44	37	43	39	45	44	46	50	
40		32	30	32	25	28	26	32	33	32	34	




FIG. 6

6 / 10

OB8 CTL assay

Target cells	% specific lysis
Auto LCL cont.	17%
Auto LCL + peptide	67%
GS LCL cont.	11%
GS LCL + peptide	36%
IM17 LCL cont.	16%
IM17 LCL + peptide	18%

FIG. 7




FIG. 8

SUBSTITUTE SHEET (RULE 26)

7 / 10




FIG. 9




FIG. 10

SUBSTITUTE SHEET (RULE 26)

8 / 10

Amino acid sequence of positive 5T4 peptides

14.2 LHLEDNALKV

14.3 LEDNALKVLH

FIG. 11




FIG. 12

SUBSTITUTE SHEET (RULE 26)

9 / 10




FIG. 13

Amino acid sequence of the shorter versions of 14.3 and 14.2 peptides

#3 HLEDNALKV

#10 LEDNALKVL

#11 LEDNALKV

FIG. 14

SUBSTITUTE SHEET (RULE 26)

10 / 10




FIG. 15

SUBSTITUTE SHEET (RULE 26)

SEQUENCE LISTING

5

SEQ ID No. 1

Feline 5T4 Coding Sequence

10 1 M P G G C S R G P A A G D G R L R L A R
ATGCCCTGGGGGTGCTCCCGGGGCCCGCGCGGAGACGGGGGGCTGCGGCTGGCGCGG
L A L V L L G W V S S S S L T S S A P S
61 CTGGCGCTGGICCTCCTGGGCTGGGTCTCTTGGTCTTCTCTCACTTCCTCGGCGCCCTCC
T S S T S F L A S A V S A Q P P L P G Q
15 121 ACCTCCTCCACGTCGTTCCTGGGCTCCGCGGTGTCGCGCCAGCCCCCGCTGCCGGGCCAA
C P Q L C E C S E A A R T V K C V N R N
181 TGCCCCAGCTTTGCGAGTGCTCCGAGCGCGCGCACTGTCAAGTGCCTTAACCGCAAC
L T E V P A D L P P Y V R N L F L T G N
241 CTGACCGAGGTGCCCGGGACCTGCCCCCTACGTGCGCAACCTCTTCCTCACCGCAAT
Q L A V L P A G A F A R R P P L A E L A
20 301 CAGCTGGCGTGCTCCCCCGCGGCTTCGCGCGCGCGCGCGCTGGCGGAGCTGGCC
A L N L S G S R L Q E V R A G A F E Q L
361 GCGCTCAACCTCAGCGGCAGCGCCTGCAGGAGGTGCGCGCGCGCGCTTCGAGCAACTG
P S L R Q L D L S H N P L A H L S P F T
25 421 CCCAGCCTGCGGACGTCGACCTCAGCCACACCGCGCTGGCGCACCTCAGCCCTTCACC
F S G S N A S F S A P S P L V E L M L N
481 TTCTCGGCGAGCAACCGCAGCTTCTCGGCCCCAGCCCCCTGGTGAAGTATGTGAAC
H I V P P E D E R H N R S F E G M V A A
541 CACATCGTGCCCTGAGGACCAACCGGACACCGGAGCTTCGAGGGTATGGTGGCGGCG
S L R A G H A L R G L Q R L E L A S N H
30 601 TCCCTACGCGCGGCCATGCGCTTCGCGGGCTCCAGCGCCTYGAAGTGGCCAGCAACCAC
F L F L P R D V L A H L P G L R H L D L
661 TTCTCTTCTTGCTCGGGACGTACTGGCCACCTACCGGGCTCAGGCACCTGGACCTG
R N N S L V S L T Y V S F R N L T H I Q
35 721 CGCAACAACCTCGCTGGTGAGCCTAACCTACGTGTCCTTCGCAACCTGACACACCTACAA
S L H L E D N A L K V L H N G T M A E L
781 AGCCTCCACCTGGAGGACAACGCCCTCAAGTCTCTCACAACGGCACCATGGCGGAGTTG
Q S L P H V R V F L D N N F W V C D C H
841 CAGAGCCTGCCCCAGTCAGGGTCTTCTGGACAACAATCCCTGGGTCTGCGACTGTGAC
M V D M V A W L K E T E V V Q G K A R L
40 901 ATGGTGGACATGGTGGCTGCTCAGGAGACAGAGGTAGTGCAGGCGAAAGCCAGGCTC
A C A F P E K M R N R A L L E L N S S H
961 GCCTGTGCATTCCCGGAAAAATGAGGAATCGGGCCCTTTTGGAACTCACAGCTCCAC
L E C D P I L P P S L Q T S Y V F L G I
45 1021 CTGAGTGTGACCTATCTCCCTCCATCCCTGCAGACTTCTTATGTCTTTCTAGGTATT
V L A L I G A I F L L V L Y L N R K G I
1081 GTTTTACCCGTATAGGTGCCATTTCTTACTGGTTTGTACTGAACCGCAAGGGGATA
K K W M H N I R D A C R D H M E G Y H Y
1141 AAAAAGTGGATGCATAACATCAGAGATGCCTGCAGGGATCATGGAAGGGTATCACTAC
R Y E I N A D P R L T N L S S N S D V *
50 1201 AGATATGAATCAACGCGGACCCAGGTAAACAAACCTCAGTTCTAATTGCGATGTCTGA

55

SUBSTITUTE SHEET (RULE 26)

SEQ ID No.2

PLADLSPFA

5

SEQ ID No.3

LHLEDNALKV

10

SEQ ID No.4

LEDNALKVLH

SEQ ID No.5

15

HLEDNALKV

SEQ ID No.6

LEDNALKVL

SEQ ID No.7

LEDNALKV

SUBSTITUTE SHEET (RULE 26)